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Abstract 
Introduction 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease common in 
postmenopausal women, characterised by the presence of serum 
antimitochondrial antibodies. Exposure to environmental xenobiotics and 
estrogenic drugs has been linked to an increased incidence of PBC and 
cholestasis respectively. We hypothesized that exposure to environmental 
xenoestrogens may be a risk factor for PBC.  
Methods 
A screening system by which compounds could be tested for transcriptional 
estrogenic activity was developed and validated. Compounds were screened for 
human estrogenic activity by dual luciferase reporter assay and by 
measurement of the induction of a known estrogen responsive gene, TFF1.  
The effects of exposure to xenoestrogens on mitochondrial function was 
assessed by MTS assay and by measurement of TMRM localization.  In vivo 
effects of exposure to xenoestrogens was examined in a range of mouse 
models.   
Results 
A number of xenoestrogens were identified, notably the azo dyes sunset yellow 
and tartrazine, however, neither of these tested positive in the classical mouse 
uterotrophic assay. Further investigations suggested that these compounds 
might have a higher affinity and/or specificity for ERβ, which may not be critical 
for sexual development and therefore potentially explains the findings of the in 
vivo assay. Both sunset yellow and tartrazine caused a significant decrease in 
hepatocyte TMRM localization and sunset yellow caused a reduction in MTS 
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reduction in primary rat hepatocytes, suggesting these compounds have a 
detrimental effect on mitochondrial function. 
In a mouse model of chronic exposure, tartrazine was found to significantly 
increase portal tract inflammation (PTI), collagen deposition and increase serum 
ALP activity, all of which are biomarkers of cholestatic liver injury. SYBR-Green 
qRT-PCR analysis revealed that both estrogen and tartrazine cause significant 
changes in the expression MRP 1-6 and other drug/bile salt transport proteins 
in the mouse liver, indicating a potential mechanism for the observed 
cholestasis. The expression of hepatic 3a11 was inhibited in this model implying 
antagonism of the pregnane X receptor.  
Conclusions 
These findings suggest that exposure to tartrazine, or other xenoestrogens may 
cause ERβ activation and PXR antagonism in the liver, resulting in altered 
transporter expression and a cholestatic injury. If this liver insult was coupled 
with damage/alteration to mitochondrial reductase enzyme function, and/or 
other genetic/environmental factors, it may be an initiating factor in PBC.
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1.1. The liver, anatomy and function 
1.1.1. Anatomy and position 
The liver is the largest gland in the human body, it performs an extensive 
number of diverse functions, many of which are essential for health and 
survival.   The liver is located in the right upper quadrant of the abdominal cavity 
and is of reddish-brown appearance, it is the shape of a rounded wedge and in 
a normal adult has a mass of between 1.2 and 1.6kg17, 18. 
The human liver is usually described to have three distinct surfaces, the 
superior, inferior and posterior.  The superior surface is attached to the 
underside of the diaphragm and the anterior abdominal wall by the falciform 
ligament, along the line of which the liver is divided into the right and left 
lobes(Fig 1.1A). The right lobe is much larger in size than the left by a ratio of 
approximately 6:1. The inferior and posterior surfaces are themselves divided 
into 4 lobes by 5 fossæ17, 18. 
1.1.1. Blood supply 
The liver receives a dual blood supply, 75% of which comes via the hepatic 
portal vein, delivering venous blood drained from the gastrointestinal tract and 
its associated organs. The remaining 25% of the blood supply to the liver is via 
the hepatic artery, providing the liver with a supply of oxygenated arterial blood. 
Both these blood vessels, along with the common bile duct, enter the organ at 
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the region named the Porta hepatis, an area under the surface of the left side of 
the right lobe. 
The blood supply empties into central veins within the liver lobules which 
converge to form hepatic veins, the blood then leaves the liver and is drained 
via the inferior vena cava17, 18 (Fig 1.1B) 
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Figure 1.1 – The liver structure.  A. Anterior view of the human liver. Adapted from 
Structure and function of the liver, e-Learning unit, St Georges, University of London5. B. 
Detail of dual blood supply to the human liver, Adapted from www.blobs.org9 
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1.2. Cells of the liver 
1.2.1. Hepatocyte 
Hepatocytes are the largest and most abundant cell type in the liver, the 300 
billion hepatocytes that form a typical adult human liver constitute approximately 
80% of the total liver mass17.  The hepatocyte is a polygonal epithelial cell, with 
a typical lifespan of 150-200 days17.  A hepatocyte can be considered to have 3 
distinct surfaces that are clearly defined by both morphology and function.  
Around a third of the surface of a typical hepatocyte membrane constitutes the 
sinusoidal surface.  The sinusoidal (basolateral) surface is specialised for 
absorptive and secretory functions by the presence of numerous microvilli some 
of which project into the space of Disse.  Approximately 15% of the hepatocyte 
surface forms the canalicular (apical) membrane, this is the secretory pole of 
the hepatocyte forming the bile cannaliculi.  The remaining 50% of the 
hepatocyte forms a smooth intercellular fissure, which is in contact with the 
space of Disse and sealed from the bile cannaliculi by tight junctions.  Both 
intermediate junctions and desmosomes, known collectively as adhering 
junctions, link neighbouring hepatocytes. These structures contain gap 
junctions facilitating intercellular exchange between neighbouring cells.  The 
hepatocyte expresses a wide variety of cell membrane transport proteins 
allowing it to perform its absorptive and secretory roles17(Fig 1.2A). 
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1.2.2. Hepatic sinusoidal endothelial cells 
Hepatic sinusoidal endothelial cells constitute 15-20% of the total cell number in 
the liver, but only around 3% of the liver volume17.  They are flat cells supported 
by a fine layer of extracellular matrix. Endothelial cells form the continuous 
lining of the sinusoid, where portal and arterial blood are combined17.   
1.2.3. Stellate cell 
Stellate cells, first described by Ito in 1951, make up 3-8% of the total liver cell 
number and lay in the area between the hepatocytes and the sinusoidal 
endothelial cells, known as the space of Disse17. Stellate cells are at their most 
abundant in zone III of the ascinus. In their normal phenotype, stellate cells 
contain an abundance of vitamin A as droplets within the cytoplasm.  In 
response to injury the stellate cell may transdifferentiate to a myofibroblast 
phenotype19.  When this occurs the stellate cell will shed its retinoids and begin 
to secrete vast quantities of extracellular matrix proteins (notably collagen type 
I, III and IV)19.  This response of the stellate cell to injury may persist, and is 
thought to be the underlying causative mechanism of hepatic fibrosis17(Fig 
1.2B). 
1.2.4. Cholangiocyte 
Biliary epithelial cells or cholangiocytes form the bile duct epithelium, their 
structure varies dependant upon the type and size of bile duct in which they are 
located.  Biliary epithelial cells are predominantly concerned with the transport 
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of bile, from where it is collected from the apical membrane of the hepatocyte, 
to where it leaves the liver via the common bile duct.  Like hepatocytes, biliary 
epithelial cells express a range of transport proteins that are essential in the 
production of bile17. 
1.2.5. Kupffer cell 
First described by K.W von Kupffer in 1898, Kupffer cells are the resident 
sinusoidal macrophages and constitute 8-12% of the total liver cells17. Kupffer 
cells are thought to be derived from monocytes, and released from stem cells 
within the bone marrow, they are most abundant in the periportal areas17.  The 
most significant functions of this cell type are phagocytosis and clearance of 
toxins, antigens and antigen-antibody complexes17. 
1.2.6. PIT cell 
PIT cells are lymphocytes with large granules and rod-cored vesicles. They are 
natural killer cells found in the liver, particularly in the sinusoids and space of 
Disse.  PIT cells are principally involved in the destruction of tumour, foreign 
and necrotic cells17.  
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Figure 1.2 – Liver Cells. A. Hepatocellular membranes. Diagram of the orientation and 
position of the hepatocyte relative to the sinusoid and the apical membrane which forms 
the bile cannaliculus.Adapted from Use of cultured cells to study alcohol metabolism, 
Clemens, D.L.8. B. Cellular events in hepatic fibrosis. Artistic representation of the 
cellular events leading to hepatic fibrosis, including the activation of stellate cells and 
deposition of collagen. Figure modified from Mac the knife? Macrophages– the double-
edged sword of hepatic fibrosis, Friedman, S.L15. 
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1.3. Functional Units 
There is no standard way of describing the functional unit of the liver, as its 
arrangement will vary depending on the perspective from which it is studied. 
The functional liver unit is usually described using one of two different models, 
the lobule or the acinus. 
1.3.1. Liver lobule 
The liver lobule, first described by Kiernan focuses on the blood flow and bile 
drainage through the liver, it can be viewed as a hexagonal unit of 6 portal 
tracts surrounding a central vein. There are typically 1.0-1.5 million of these 
lobules in the adult liver17, 20(Fig 1.3). 
1.3.2. Liver acinus 
The liver acinus describes a smaller functional unit than the lobule that is better 
used to illustrate the metabolic and secretory roles of the liver. First described 
by Rappaport, the acinus describes a field with the portal tract at its centre, 
radiating to the central vein. The acinus itself can be separated into 3 zones, 
with zone I being the closest to a portal tract, and therefore the richest in O2 and 
zone III closest to the central vein17, 21(Fig 1.4A). 
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1.3.3. Portal tract 
The portal tract is a distinctive arrangement of branches of the hepatic artery, 
portal vein, bile ducts and lymphatic vessels. These vessels, along with a 
branch of the vagus nerve, are encased in perivascular connective tissue. The 
portal tract is directly surrounded by a continuous layer of specialised 
hepatocytes which is designated the limiting plate17, 22(Fig 1.4B).  
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Figure 1.3 – The liver lobule. The structure of the liver lobule. Blood enters the lobule 
through branches of the portal vein and hepatic artery and flows through the sinusoid 
passing the absorptive surface of the hepatocytes before leaving the liver via the central 
vein. Adapted from Energy availability and alcohol-related liver pathology, Cunningham, 
C.C.9 
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Figure 1.4 – Liver ascinus and portal tract. A. The liver ascinus. Diagram of the 
liver ascinus, the area between a specific portal tract and the central vein. Shown are 
the three ascinar zones, defined by their relative blood oxygen levels. B. The portal 
tract. Magnified view of a portal tract (A) relative to the liver lobule (B), modified from 
John Hopkins Medical, Gastroenterology and Hepatology7. 
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1.4. Functions of the liver 
1.4.1. Glycogen formation, storage and release 
One of the major functions of the liver is storage of chemical energy in the form 
of glycogen.  When dietary carbohydrates are catabolised, causing glucose to 
accumulate in the blood, insulin secretion from the pancreas is initiated.  As 
blood enters the liver, insulin stimulates the liver to take up glucose. Glucose 
molecules are then modified to form chains of glycogen, which are stored within 
the hepatocytes. Providing blood levels of both glucose and insulin remain high, 
the liver will continue to store glycogen. Stored glycogen may comprise up to 
8% of the total wet liver weight (around 80g), this is enough to maintain glucose 
homeostasis for up to 10 hours17.  
When blood glucose levels decrease during periods of fasting, the pancreas will 
begin to secrete increasing amounts of glucagon, a hormone which stimulates 
the release of glucose into the blood17. 
1.4.2. Biotransformation 
The liver is the main site of elimination of both endogenous and exogenous 
substances from the body that are either not required or are potentially harmful. 
The detoxifying roles of the liver have long been established but the 
mechanisms utilised in the conversion of toxic substances are now termed 
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metabolism, because of the potential for the same processes to create harmful 
products from toxic substances17.  
Many of the metabolic activities performed by the liver are biotransformation 
reactions. This refers to the biochemical alteration of a substance, which allows 
the conversion of lipophillic substances to excretable water-soluble metabolites.  
Biotransformation of both endogenous and exogenous substances may occur in 
many different organs, but mostly occurs in the liver23, 24. 
The process of biotransformation occurs in two steps, or phases. Phase 1 
reactions, also termed functionalisation reactions, generally increase the water 
solubility of a compound, often through formation of a hydrophilic group on the 
target (hydroxyl, carboxyl, sulphydryl or amine group) by one of 4 processes: 
oxidation, reduction, hydrolysis or hydration.  A large proportion of the phase 1 
oxidation reactions are performed by enzymes from the cytochrome P450 family 
(CYP). There are an extensive number of different CYP enzymes, derived from 
over 50 separate genes with different substrate specificities. CYP are the major 
enzymes involved in drug metabolism and bioactivation, because of the varying 
expression of CYP between individuals they are highly implicated in some 
cases of adverse drug reactions and non-response to treatment due to varying 
metabolism, detoxification or bioactivation23, 24. 
In phase 2 reactions, the product formed in phase 1 is conjugated with an 
endogenous substance by specific transferase enzymes. Phase 1 metabolites 
may be conjugated with glucuronic, sulphate, acetic or amino acids, S-adenosyl 
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methionine or mercaptopuric acid derivatives.  The resulting conjugates are 
highly hydrophilic and therefore readily excretable via the urine or bile23, 24. 
1.4.3. Bilirubin metabolism  
Bilirubin is an organic anion, produced from the breakdown of haem, primarily 
from erythrocytes in the spleen. Bilirubin is an apolar lipophillic substance and is 
potentially toxic, it is bound to serum albumin and transported to liver where it is 
detoxified by hepatocytes17, 23, 24. 
Bilirubin is transported across the sinusoidal membrane of the hepatocyte, at 
which point the albumin is separated.  The free bilirubin is detoxified by 
conjugation with glucuronic acid in the smooth endoplasmic reticulum, mediated 
by UDP-glucuronyltransferase. The product of this reaction is water-soluble 
secondary bilirubin that is eliminated through the bile17, 23, 24 (Fig 1.5A). 
1.4.4. Amino acid and protein metabolism 
There is an average turnover of approximately 650g/day of the body’s amino 
acid pool.  The majority of the degradation of amino acids occurs in the liver 
through transamination and oxidative deamination reactions17, 23, 24. 
1.4.5. Lipid metabolism 
The liver performs a variety of different functions in the metabolism of lipids, 
these include the uptake, oxidation and transformation of free fatty acids and 
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the synthesis of plasma lipoproteins essential for transport of lipids in the 
aqueous environment of the blood.  The liver can also synthesise glucose from 
the glycerol molecule found in the triglycerides stored in fatty tissue, through the 
process of lipolysis17, 23, 24. 
85% of the body’s supply of cholesterol is also formed in the liver, cholesterol is 
critical in the formation of cell membranes, and is the initial substrate in the 
biosynthesis of bile acids via cytochrome p-450 mediated oxidation, vitamin D 
and steroid hormones17, 23, 24. 
1.4.6. Hormone metabolism 
The liver contributes towards the inactivation of hormones and subsequently the 
maintenance of hormonal homeostasis. The elimination of the steroid hormones 
– glucocorticoids, androgens and estrogens occurs primarily in the liver via an 
array of enzymatic reactions which increases their polarity to aid excretion in the 
bile or urine. Steroid hormones may be sulphated by sulphotransferase 
enzymes, glucuronidated by uridine diphosphate-glucuronosyltransferases or 
hydroxilated by cytochrome p-450 mono-oxygenase enzymes 17, 23-25. 
1.4.7. Xenobiotic metabolism 
Any xenobiotic in the gastrointestinal tract and some in the blood system will 
travel directly to the liver because of its functional role and position. This makes 
the liver the major site of xenobiotic, and therefore drug, metabolism.  The 
metabolic enzymes used in the detoxification of endogenous substances are 
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also utilised in the metabolism, clearance and also bioactivation of 
xenobiotics17, 23, 24. 
The metabolic function of the liver may also be altered by exposure to 
xenobiotics, which may induce or inhibit expression or function of certain 
metabolising enzymes17, 23, 24.   
1.5. Biliary system 
Hepatocytes actively transport bile acids from the blood in a process facilitated 
by transporters at the hepatocyte basolateral membrane 16, following uptake 
into the hepatocytes, bile acids may be modified within the hepatocytes forming 
the component parts of bile. The newly formed bile salts are actively transported 
across the apical membrane of the hepatocyte, in to the channel formed 
between two neighbouring cells, sealed by tight junctions. This has the effect of 
concentrating the bile salts in what is termed canaliculi, the osmotic gradient 
produced by this action is sufficient that water simultaneously diffuses into the 
canaliculi, producing bile. The newly formed bile is moved along the tiny 
canaliculi by the peristaltic movement of the actin-myosin network lying beneath 
the canalicular membrane of the hepatocytes. The canaliculi converge into an 
extension connecting them together, this intermediate ductule is referred to as 
the canal of Hering26.  From the canal of Hering onwards, the bile ductules have 
their own specialised epithelial lining, formed from cholangiocytes. The bile 
flows from the canal of Hering into the preductules, the smallest duct of the 
biliary tract (5-20µm in diameter). From the preductules onwards, the ducts get 
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progressively larger in size. Terminal ductules join interlobular bile ducts that 
run along the portal tracts collecting into a channel which drains through a 
network of small intrahepatic bile ducts, before converging in the common bile 
duct (CBD) and subsequent transport of bile away from the liver 26. 
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Figure 1.5 – Biliary system and function. A; Bilirubin metabolism Schematic of the 
metabolism of bilirubin to bilirubin diglucuronide by UGT1A1 adapted from Adaptive 
evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes, 
Li, C. Wu, Q.10. B; Bile flow. Diagram showing the network of bile ducts which transport 
the bile formed by hepatocytes away through the bile canaliculi to the larger bile ducts in 
the portal tract, adapted from accessscience.com14. 
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1.6. Cholestasis  
Cholestatic liver disease refers to a condition that occurs as a result of an 
interruption or impairment to the normal flow of bile through the liver.  Bile is a 
naturally occurring yellow alkaline fluid, normally around pH 8, which is 
essential for the digestion of dietary lipids.  Bile is formed by hepatocytes and 
transported through the network of intrahepatic bile ducts within the liver. The 
newly formed bile exits via the common bile duct, up to 50ml of bile is stored in 
the gall bladder of an adult.  When required, the bile is released into the 
duodenum where it acts as a surfactant to aid the digestion of dietary fats.  Bile 
salts have both a hydrophobic and hydrophilic pole allowing them to interact 
between lipids and the aqueous environment of the small intestine. Bile aids the 
dispersion of the fat into micelles, thus creating a much larger surface area for 
other digestive enzymes to act upon17. 
Occasionally the normal flow of bile through the liver may become interrupted, 
resulting in a disease condition known broadly as cholestasis.  Taken from the 
Greek chole (bile) and stasis (standing still), cholestasis may arise from any of a 
large number of different situations. Common circumstances in which 
cholestasis may occur include physical obstruction or damage to the common 
bile duct, obstetric cholestasis, gallstones, primary biliary cirrhosis or as a side 
effect of some prescription drugs27 28. The result of cholestasis is an elevation of 
the serum concentration of bile acids which causes the symptoms of pruritus, 
an intense itching of the skin, fatigue, lethargy and jaundice28.  
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Table 1.1 –Bile acids. A summary of the common bile acids which constitute bile, 
showing their chemical structure and relevant information. 
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1.7. Primary biliary cirrhosis 
Primary biliary cirrhosis (PBC) is a chronic, slowly progressive form of 
cholestatic liver disease of unknown cause, characterised by persistent, 
irreversible inflammation and destruction of small intrahepatic bile ducts, which 
may result in cirrhosis and ultimately failure of the liver 29, 30(Fig 1.6). Whilst a 
significant proportion of PBC patients are asymptomatic at the time of 
diagnosis, others complain of debilitating fatigue and pruritus, often preceding 
any indication of impaired liver function 31, 32. Previous research and clinical 
observation has highlighted a broad array of immune mediated symptoms and 
phenomena, synonymous with an autoimmune aetiology33. 
In PBC, cholestasis is accompanied by a persistent inflammation of the small 
interlobular and septal bile ducts (those less than 100µm in diameter). This 
causes severe, persistent and irreversible damage to the biliary epithelial cells 
that form the epithelial lining of the ductules.  PBC may ultimately result in the 
total destruction, or “vanishing” of the ducts.  Interestingly this effect seems 
specific to the smaller bile ducts, with the medium and large type remaining 
undamaged 34.  The disease state may progress from localised fibrosis, to 
cirrhosis and in the most severe cases total failure of the liver 35. 90% of cases 
of PBC are observed in women, nearly always in those between the age of 40 
and 59 at the time of presentation36. 
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1.7.1. Diagnosis of PBC 
Suspicion of PBC arises when cholestasis is observed in postmenopausal 
women that is not caused by mechanical cholestasis, which is confirmed by 
ultrasound examination.  Accompanying the usual symptoms of cholestasis, 
elevated serum alkaline phosphotase (ALP), aspartate aminotransferase (AST) 
and bilirubin may be observed23.  The gold standard in diagnosis of PBC is by 
liver biopsy, which will reveal the unique inflammatory infiltration of the small 
bile ducts, and possibly granulomas and copper deposits which collect in the 
liver along with other components of bile, as a result of the cholestasis. It is also 
important to note that some clinical signs of PBC currently used as diagnostic 
markers are not present in all cases, nor are they always concordant with the 
severity of liver damage 32. 
Diagnosis of PBC may also be based upon the identification of serum 
antimitochondrial antibodies (AMA), 95% of Caucasian PBC patients have AMA 
specific for mitochondrial pyruvate dehydrogenase complex enzymes, primarily 
the E2 subunit (PDC-E2). The presence of AMA in PBC forms the basis of the 
suggestion that PBC may be an autoimmune disease37. The enzymatic 
reactions catalysed by PDC enzymes are summarised in Fig 1.6B. 
 As up to 50% of PBC patients do not outwardly show any symptoms at the time 
of diagnosis, the disease may be identified only through biochemical markers 
flagged by chance, or as a result of routine check up 35. Identification of PBC by 
physical examination may not be possible until the disease has progressed into 
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the latter phases, at which point portal hypertension and pigmentation of the 
skin, caused by exaggerated melanin deposition, may be observed. Upon 
progression, the physical indices of liver failure; enlarged liver, spleen and 
ascites may be seen 32. 
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Figure 1.6 – Primary biliary cirrhosis. A. PBC histology. Haematoxylin and Eosin 
stained Tissue section from the liver of a PBC patient showing the inflammatory cell 
infiltrate and damage/ destuction of the bile duct epithelium and disappearing bile duct 
(arrow), taken from The Liver Centre6. B. Pyruvate dehydrogenase complex reactions. 
Schematic of the reactions catalysed by PDC enzymes to convert pyruvate to Acetyl-CoA 
and NADH, adapted from Pyruvate dehydrogenase multienzyme complex12 
. 
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1.7.2. Therapeutic strategies in PBC 
Effective drug treatments for PBC are limited and currently no cure for the 
disease has been identified38.  Therapeutic strategies mainly focus on the 
management of the symptoms of the disease. The most common treatments 
are administration of the naturally occurring bile salt ursodeoxycholic acid 
(UDCA), immunosupression or a combination of the two.   
First observed by Lueschner in 1981, treatment with 13-15mg/kg body weight of 
UDCA has been shown to improve serum biochemical markers of PBC 39, 
increase 10 year patient survival 40 and reduce the fibrosis seen in the early 
stages of disease progression 41, The exact mechanism by which UDCA exerts 
a positive effect is unclear, it is likely that it causes a modification of the 
recycling bile acid pool, resulting in a more hydrophilic environment. The net 
result of UDCA treatment may be to promote the formation of bile with a lower 
concentration of the more harmful naturally occurring bile salts.   
Another treatment strategy employed in PBC is immunosuppression.  The 
rational for use of immunosuppressive treatment is based upon the 
identification of the autoimmune hallmarks of PBC. A variety of different 
strategies have been investigated, using common immunosuppressive drugs42.  
Corticosteroids: prednisolone treatment has been shown to improve serum 
ALP and AST, but no change in the serum bilirubin levels or severity of pruritus 
has been observed43. 
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Azathioprin: Treatment with the classical immunosuppressant drug azathioprin 
has yet to show any significant effects in cases of PBC44. 
Cyclosporin A: Mixed reports surround the effectiveness of cyclosporin A in 
PBC, a small study of a cohort of 20 patients suggests an improvement in 
histology following 2 years of treatment.45  The widespread use of cyclosporine 
A would be ill advised due to its potential for severe side effects. 
D-penicillamine:  A common characteristic of PBC is the accumulation of 
copper in the bile, with this in mind the copper chelator, d-penicillamine, has 
been previously trialled.  D-penicillamine also has immunosuppressive and anti 
fibrotic properties and would seem to be an attractive therapeutic option.  Over 
6 studies totalling 748 patients, no positive therapeutic effect was observed but 
30% of patients experienced severe side effects46.  
Methotrexate: Commonly used for immunosuppressive purposes, and also 
effective at providing symptomatic relief in rheumatoid arthritis, methotrexate 
therapy has been previously tested in PBC. In a study of 60 patients, low dose 
(7.5mg/week) led to an improvement of biochemical markers with the exception 
of bilirubin.  No effect was seen regarding the overall severity of the disease, 
necessity for transplantation or patient survival47. 
In principle immunosuppressant therapy seems to be a good strategy for PBC, 
but only a few drugs offer any improvement, and even those effects are mainly 
upon patient serum biochemistry, not on disease severity or progression. 
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With immunosuppression proving ineffective, UDCA remains the primary 
strategy for treatment of PBC, but sometimes patients do not respond to UDCA 
alone.  Non-responders are defined as those who show unaltered progression 
of PBC to cirrhosis and portal hypertension despite UDCA therapy, in these 
cases combination therapy may be considered42. 
Steroids and UDCA: In a randomised study of 30 patients receiving 10mg/day 
of prednisolone alongside UDCA, a significant improvement in inflammatory 
activity was observed48. UDCA accompanied by 9mg/day budesonide showed 
both biochemical and histological improvements amongst 39 patients49. 
Sulindac and UDCA: Over 12 months of treatment with a combination of 
sulindac and UDCA, again both biochemical and histological improvements 
were observed50. 
Colchinine and UDCA: Two studies in the 1990’s51, 52 of combination therapy 
using colchinine and UDCA totalling 118 patients resulted only in mild 
biochemical improvements. 
Other drug therapeutic strategies are limited, although one possible alternative 
is treatment with a selective estrogen receptor modulator (SERM). Tamoxifen 
has previously been suggested as a potential treatment, based on clinical data 
from patients who were diagnosed with PBC and also subsequently 
administered tamoxifen for the treatment of breast cancer 34.  The macrolide 
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antibiotic, Rifampicin, has also been trialled in PBC patients and showed 
moderate success in management of symptoms53. 
The mechanism of action in the case of both tamoxifen and rifampicin may 
possibly be due to the anti inflammatory action of the activation of the orphan 
nuclear receptor transcription factor, the pregnane X receptor (PXR).  Both of 
these drugs are known PXR agonists 54 55 and PXR activators such as 
rifampicin  have previously been shown to be beneficial in experimental models 
of fibrotic liver disease 56-58. It is also possible that the increased P450 
expression resulting from PXR activation increases the level of bile acid 
metabolism and clearance53.  
Where no other treatment method has proven effective and the condition is 
progressing to end stage liver failure, transplant may be the only remaining 
option.  The appropriate timing of transplant in cases of PBC can be judged 
based on serum bilirubin levels, it has been suggested that post transplant 
survival is at a peak if surgery is performed before serum bilirubin levels exceed 
170µmol/l 59. Liver transplant is most successful in cases of PBC compared to 
other liver diseases, with an expected 85% survival rate 32. 
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1.7.3. PBC as an autoimmune disease 
The cause of the initial inflammatory response, which initiates the development 
of PBC is currently unknown, it is still widely accepted that PBC is of 
autoimmune pathogenesis.  Whilst PBC undoubtedly exhibits several hallmarks 
indicative of a classic autoimmune condition, more recent work has begin to 
challenge this concept suggesting that there is a more complex pathway 
involved 29. 
PBC is widely thought of as an autoimmune condition, often characterised by 
the detection of anti-mitochondrial antibodies AMA. AMA are specifically 
targeted at oxoacid dehydrogenase complex (OADC) antigens37, 60. The OADC 
family of mitochondrial proteins consists of three major subunits, pyruvate 
dehydrogenase (PDC), branched chain ketoacid dehydrogenase (BCKD) and 
ketoglutarte dehydrogenase (ODG).  Each enzyme consists of three unique 
subunits, each with a specific enzymatic activity: E1 (decarboxylase), E2 
(dihydro lipoamide acyltransferase) and E3 (lipoamide dehydrogenase)61. 
These antigens are enzymes found localised within the inner mitochondrial 
matrix, which catalyze oxidative decarboxylation reactions. 
In around 90% of caucasians, PBC patient sera AMA activity is solely directed 
upon pyruvate dehydrogenase complex E2 subunit (PDC-E2)29, 62. In 
approximately 50% of PBC patients, serum AMA are also cross reactive with 
epitopes upon the E2 subunit of both BCKD and OGD. Bile AMA are always 
directed towards the same epitopes as their serum AMA counterparts63, 64. 
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In cases of PBC a MHC class II antigen has been identified upon the 
cholangiocyte membrane. It is possible that the recognition of this antigen 
initiates an intense and localised immune response mediated by circulating T 
cells, resulting in persistent portal infiltrate, inflammation and the subsequent 
destruction of the duct 65.  
The evidence supporting PBC to be a classical autoimmune disease, although 
well documented, is not without opposition. Firstly OADC are present in all 
nucleated cells and AMA are widely distributed throughout the body, yet the 
response is organ specific and localised predominately to the small bile ducts. 
Secondly AMA are not present in all cases of PBC, suggesting they cannot be 
solely responsible for the condition. 65. 
Unlike other “classical” autoimmune diseases PBC has never been convincingly 
described in children, and as previously highlighted, and as described 
previously, PBC patients do not respond effectively to treatment with 
immunosuppressant drugs 66. 
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1.7.4. Xenobiotic exposure and PBC 
In recent years, emerging research has linked exposure to environmental 
xenobiotics as a potentially causative agent in the development of PBC.  
It has been suggested that following exposure, a xenobiotic may either 
conjugate with or entirely replace the E2 component of PDC forming an 
unrecognised structure. It has been suggested that this altered protein may 
initiate an antibody response against the newly created conjugate and also 
against the native form, suggesting a loss of self-tolerance to PDC-E2.  It has 
been shown that AMA positive patient serum reacts with synthetically modified 
PDC-E2 proteins conjugated with xenobiotics with higher affinity than the native 
form. 
A good illustration of this process, known as molecular mimicry, is the 
xenobiotic induced liver disease halothane hepatitis, sometimes seen following 
exposure to the volatile anaesthetic, halothane. Halothane exposure may result 
in the formation of trifluoroacetylated (TFA) proteins which can induce an 
immune response against not only themselves but the host PDC-E2, this 
example also suggests that PDC-E2 may be susceptible to this type of 
modification67. 
It has been widely reported that exposure to particular groups of xenobiotics 
and environmental toxins may increase an individuals susceptibility to 
developing PBC. Correlations have previously been made linking tobacco 
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smoke, cosmetic products, and exposure to many other environmental 
contaminants with a heightened risk of developing the disease.  Supporting this 
idea, cluster analysis has shown that there is also a higher prevalence of the 
disease near some heavily industrial areas and toxic waste disposal 68-70. 
A good example of a xenobiotic that may be implicated in PBC is 2-octynoic 
acid, a chemical widely found in cosmetics including perfume, lipstick and also 
in common food flavourings.  It has been shown that this particular xenobiotic 
has the potential to conjugate to the lipolyl domain of PDC-E2 forming a 
modified protein. This 2-octynoic acid conjugated PDC-E2 complex is more 
highly reactive with PBC patient sera than that of controls 68. 
1.7.5. Estrogens and PBC 
Estrogen signalling may be linked to an array of cholestatic liver conditions. 
Estrogenic compounds, such as hormonal contraceptives and also high levels 
of circulating estrogen such as those seen in pregnancy, can result in 
cholestatic liver diseases, including pregnancy cholestasis and PBC 28, 71. The 
incidence of estrogen cholestasis varies with geographical location and 
ethinicity. Most notably is the incidence of intrahepatic cholestsasis of 
pregnancy which is most common in Chile and has been attributed to both 
genetic and environmental factors72. 
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1.8. Estrogen 
Estrogens are a group of steroid hormones, usually described as the primary 
female sex hormones, summarised in Table 1.2.  Estrogens are primarily 
implicated in the process of female sexual development and regulation of the 
menstrual cycle, but are also present in males and have a wide variety of other 
functions including regulation of cellular growth and differentiation1-3. 
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Table 1.2 – Estrogens. Chemical structures and relevant information regarding the 3 
naturally occurring estrogens and the modified synthetic estrogen, ethinyl estradiol.1-3. 
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1.8.1. Mechanisms of estrogen signalling 
The classical estrogen signalling pathway is via direct binding of a ligand to the 
estrogen receptor (ER), and subsequent translocalisation and binding to 
estrogen response elements (ERE) in the regulatory regions of estrogen 
responsive genes.  The ligand-ER-ERE complex is then joined by various co 
regulators, which initiate transcriptional responses to estrogen signalling.  The 
consensus ERE is a 5-base pair (bp) palindrome separated by a 3-bp spacer: 
GGTCAnnnTGACC73-76.   
Another mechanism by which estrogen may modulate gene transcription is by 
transcription factor crosstalk, where ERs interact with other transcription factors, 
such as activator protein-1 (AP-1) and specificity protein-1 (SP-1)77. 
It is also understood that estrogen signalling may occur through non-genomic 
mechanisms, taking place much more rapidly, hence sometimes referred to as 
rapid signalling.  This form of signalling has been shown to utilise a variety of 
membrane bound proteins including protein kinases A and C, MAP kinase, and 
membrane localised ERs, forming signalling cascades78, 79. 
More recently an orphan G protein-coupled receptor (GPR) GPR30 was shown 
to mediate nongenomic estrogen signalling through interaction with the novel 
ER variant ERα36, which acts as an extranuclear ER80, 81 (Fig 1.7). 
1.8.2. Estrogen receptor 
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There are two subtypes of the human estrogen receptor (ER), ERα and ERβ, 
each is derived from a distinctly separate gene. Of the two forms there are 
many different splice variants forming numerous unique ERs, each may differ in 
its action, tissue distribution or affinity for ligand, usually described as an affinity 
for the naturally occurring estrogen, 17β- estradiol (E2). Both ERα and ERβ 
share similar functional domains and significant sequence homology73, 74, 76, 82.  
The ER consists of six distinct domains, named A-F. The combined A and B 
domain encodes activation function 1 (AF1) and is located closest to the N 
terminal, this area is implicated in estrogen related transcriptional activity. The C 
domain is the DNA binding region of the ER and has the greatest sequence 
homology between α and β forms (97%). The D domain is a hinge region. The 
ligand-binding domain (LBD) is the E region encodes activation function 2 (AF2) 
this area 55% conserved between the two receptor types. AF2 within LBD 
constitutes the ligand dependent transcriptional regulatory function of ER.  The 
function of the F domain, located nearest to the C terminal, is not fully 
understood, but it is believed that this area plays a regulatory role in ER 
dimerisation and transcriptional activity 83. 
In the classical estrogen signalling mechanism, ligand binding to ER induces 
dimerisation of the receptor. The two forms of ER can form homodimers, each 
with independent activities, or influence each others activity via 
heterodimerisation. The subsequent DNA interaction and recruitment of co 
activators, causes the change in the transcription of estrogen responsive 
genes84.
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Figure 1.7 – Estrogen receptor signalling. Diagram showing common mechanisms of 
estrogen receptor signalling “Classical” pathway of binging of estrogen to nuclear 
estrogen receptor and binding to estrogen response elements (1) Binding of estrogen no 
membrane localised estrogen receptors and subsequent interaction with of MAP/ P13 
kinases or G-protein coupled receptors mediating rapid signalling mechanisms (2,3). 
Adapted from Estrogen Receptors: Therapies Targeted to Receptor Subtypes11 
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1.8.3. Modulation of estrogen signalling 
Estrogen signalling has been a therapeutic target for many years, alterations of 
the level of estrogen signalling or modulation of parts of the estrogen signalling 
pathways have long been used in the treatment of many different conditions.  
From the oral administration of synthetic estrogens for contraceptive purposes, 
to inhibition ER activity by use of ER antagonists in the treatment of breast 
cancer, there are a large number of drugs available for influencing estrogen 
signalling. 
There is a comprehensive range of estrogenic drugs available which act as a 
ligand for the ER, a commonly used estrogenic drug is ethinyl estradiol (EE).  
EE is an orally bioactive estrogenic drug, commonly used in almost all 
formulations of combined oral contraceptives.  When administered orally the 
liver rapidly inactivates E2. The structure of EE is modified by a substitution of 
estrane for ethinyl at C17, forming an estrogen which is much more resistant to 
metabolism85, 86. 
1.8.4. Selective estrogen receptor modulators (SERM) 
Inhibition of estrogen signalling is usually achieved by administration of an ER 
antagonist.  Two of the first drugs classified as estrogen receptor antagonists 
were tamoxifen and raloxifene.  These drugs were developed to competitively 
displace estradiol from ER in breast cancer cells.  It quickly became apparent 
that the pharmacology of these drugs was more complicated.  The effects of 
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these early drugs were observed to differ between different tissues, having the 
ability to exert either partial or full antagonist activities87. In the late 1980s, 
Gottardis and Jorden showed by a series of xenograft models of breast cancer, 
that tamoxifen initially functioned as an antagonist, but over time the tumours 
developed resistance to the drug, and eventually recognised the ligand-ER 
complex as an antagonist87. It was for this reason that drugs such as tamoxifen 
became known as selective estrogen receptor modulators (SERM) rather than 
as ER antagonists87. 
1.8.5. Selective estrogen receptor degraders (SERD) 
Some of the newer drugs that have been designed to decrease the level of 
estrogen signalling, such as fulvestrant (ICI 182780), are termed selective 
estrogen receptor degraders (SERD).  As the name suggests, SERD interact 
with ER and influence ER turnover.  As with some SERM, fulvestrant has a high 
affinity for both ERα and ERβ, but only increases turnover of ERα.  This is a 
good example of how despite the highly conserved sequence holomology 
between the two different receptor subtypes, they can have distinctly diverse 
functions87. 
1.8.6. Measurement of estrogenic activity 
It may be necessary to assess the degree of estrogenic activity of a certain 
compound or substance. There are different established methods by which this 
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can be done, most of which focus on the classical estrogen signalling pathway 
and subsequent effect upon gene transcription. 
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1.8.7. Measurement of an estrogen inducible gene 
A common method by which estrogenic activity can be assessed is by in vitro 
analysis of the transcription level of a known estrogen inducible gene in an 
estrogen responsive cell line. An example of this is to measure the induction of 
Trefoil Factor 1 (TFF1, previously termed pS2) mRNA induction in the estrogen 
responsive breast cancer cell line, MCF788, 89.   
1.8.8. In vivo analysis of estrogenic activity by mouse uterine 
bioassay 
The classical method by which estrogenic activity is assessed, and often 
defined, is by mouse uterine bioassay.  This method involves the administration 
of the substance of interest to prepuberal female mice, usually 19 days of age90, 
91
.  The animals receive either vehicle control or treatment by intra peritoneal 
injection for up to for 5 days, at which point they are euthanised. The uterus of 
each mouse it then excised and its wet weight relative to body mass is 
calculated.  A classical estrogenic substance will cause a significant increase in 
the weight of uterus, along with other uterotropic changes, including an increase 
in depth of the uterine epithelium90, 91. 
1.8.9. Estrogen signalling and cholestasis 
Estrogen signalling influences transcription of many genes, some of which may 
be important in cholestatic liver diseases such as PBC. Particularly significant 
are the changes of expression of the hepatocyte transport proteins, bile salt 
Chapter 1 - Introduction 
43 
export pump (BSEP) and p-glycoprotein (p-GP).  Expression of both of these 
transporters has been reported to decrease following treatment with estrogen in 
the rat. This change in transporter expression may also cause impaired flow of 
bile from the liver and therefore cholestasis.  This suggests a potential 
mechanism explaining estrogen induced cholestasis 16(Fig 1.8). 
It is understood that ER activation can increase expression of the ER in certain 
cell types92 . It has been shown that estrogen administration, and in cholestasis 
and PBC there is an increase in ER (particularly the ERβ) expression in 
cholangiocytes92 .  This activity could form the basis of a positive feedback loop, 
in which estrogen cholestasis causes an increase in receptor expression, 
intensifying the severity of the condition 92 . 
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Figure 1.8 – Estrogen Cholestasis. A. Estrogen cholestasis in the rat. Basic 
parameters of ethinyl estradiol induced cholestasis in the rat following treatment with 
5mg/kg EE, adapted from Ethinylestradiol treatment induces multiple canalicular 
membrane transport alterations in rat liver, Bossard et al.13 B. Effect of EE on 
membrane transport proteins in the rat liver. Data showing the altered expression of 
hepatic transporter proteins in the rat liver following treatment with 5mg/kg EE, adapted 
from Expression of the bile salt export pump is maintained after chronic cholestasis in 
the rat. Lee et al.16 
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1.8.10. Xenoestrogens and PBC 
A large number of environmental pollutants and xenobiotics are known to have 
estrogenic activity. Known xenoestrogens include various pesticides, 
insecticides and weed killers such as DDT, and tartrazine, a common food 
additive, and compounds routinely found in cosmetics such as the family of 
parabens which are widely used as preservatives93 94. Given the links which 
have been formed between xenobiotic exposure and PBC, we hypothesised 
that the cholestasis seen in PBC could be related to estrogenic activity of these 
xenobiotics.  
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2. Chapter 2 - Materials and Methods 
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2.1. Animals  
2.1.1. Rats 
Sprague-Dawley rats were purchased from Harlan or Charles River (both UK) 
and were housed in the Comparative Biology Centre at Newcastle University. 
Rats were kept in an air-conditioned environment of 20oC ± 3oC with a 
controlled humidity of 50% ± 10% and a 12hr light/dark cycle. Animals were 
cared for as per Home Office regulations. 
2.1.2. Foetal tissue 
Female rats were mated, taking the time of formation of the vaginal plug as time 
of conception. Between 12 and 16 days of gestation foetuses were obtained 
from pregnant females after CO2 asphyxiation and cervical dislocation. 
Foetuses were pooled and snap frozen in liquid nitrogen prior to 
homogenisation and RNA isolation.  
2.1.3. C57Bl6 wild type mice 
Mice were purchased from Harlan or Charles River (both UK) and housed in the 
Comparative Biology Centre at Newcastle University. Mice were kept in an air-
conditioned environment of 20oC ± 3oC with a controlled humidity of 50% ± 10% 
and a 12-hour light/dark cycle. Animals were cared for as per Home Office 
regulations.  
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2.1.4. Prepubescent C57Bl6 mice 
For investigations utilising prepubescent C57Bl6 mice, breeding cages of the 
ratio 2 females: 1 male were established within the Comparative Biology Centre 
at Newcastle University, the date of birth of each litter was recorded. Animals 
used for study were identified by an ear notch and remained with the rest of the 
litter until old enough to be weaned. 
2.1.5. Mouse uterine bioassay 
Female mice were sexed and identified by ear notching before 19 days of age, 
on day 19 animals were administered treatment by a single daily intra peritoneal 
injection on 4 consecutive days. On day 5, animals were sacrificed by Schedule 
I method and their uteri harvested for analysis. 
2.1.6. Serum enzyme assays 
Serum samples were collected by tail bleeding, and by terminal bleed after 
autopsy. Blood was allowed to clot and then centrifuged at 13 000rpm, the 
serum was collected and analysed by the Clinical Biochemistry Department at 
the Royal Victoria Infirmary, Newcastle. 
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2.2. Cell Culture  
2.2.1. Primary rat hepatocyte isolation 
Male Sprague-Dawley rats (150 - 200g) were anaesthetised by i.p. 
administration of 100mg/kg Sagatal (sodium pentobarbital) solution.  An incision 
was made along the midline of the animal, a 19G cannula was inserted into the 
portal vein and secured with 2 ligatures, the vena cava was then severed to 
allow perfusate to exit. The liver was first perfused with 300mls of 25mM 
ethylene glycol tetraacetic acid (EGTA) solution in Earle’s balanced salt solution 
(EBSS) (without Mg2+ and Ca2+, with NaHCO3). Whilst the organ blanched it was 
excised from the animal and placed in a sterile 10cm Petri dish. The liver was 
then perfused with 200mls EBSS (without Mg2+ and Ca2+, with NaHCO3) at 
37°C. Finally the liver was perfused with 0.5mg/ml collagenase A from 
Clostridium histolyticum solution in EBSS at 37°C, this perfusate was re-
circulated until the optimum level of digestion was achieved. 
The perfused liver was disrupted into the remaining collagenase A solution, the 
liberated cells were then passed through a 75 µM nylon mesh and suspended 
in William’s Medium E (WME). The isolated cells were centrifuged at 50g for 5 
minutes before washing in WME and one further centrifugation and re-
suspension in WME.  Cells were counted using a haemocytometer and cell 
viability determined by trypan blue exclusion.  Cell yield routinely exceeded 
500x106 cells per liver and viability > 90%. 
Chapter 2 – Materials and Methods 
50 
 
Primary rat hepatocytes were seeded in WME supplemented with 80U/ml 
penicillin, 80U/ml streptomycin, 2mM L-glutamine, 1% (v/v) insulin transferrin 
selenium solution (ITS) (final concentrations: 10 µg/ml insulin from bovine 
pancreas, 55 µg/ml human transferrin, 50 ng/ml sodium selenite) and 10% (v/v) 
foetal bovine serum (FBS) for up to 24hrs whilst they adhered.  Hepatocytes 
were then maintained in serum free WME supplemented with 80U/ml penicillin, 
80U/ml streptomycin, 2mM L-glutamine and 1% (v/v) ITS (final concentrations: 
10 µg/ml insulin from bovine pancreas, 55 µg/ml human transferrin, 50 ng/ml 
sodium selenite). Cell culture media was replaced every 24 hours. 
2.2.2. Preparation of cell cultures from the rat biliary structure 
Following rat hepatocyte isolation, the remaining tissue was incubated in a 
1mg/ml solution of collagenase A at 37°C and agitat ed by shaking at 250rpm for 
1 hour. The liberated biliary structure was then disrupted into small pieces using 
a scalpel, then incubated in 1mg/ml solution of pronase at 37°C and agitated by 
shaking at 250rpm for 1 hour.  The cell suspension was passed through a 75µM 
nylon mesh and centrifuged at 2000rpm for 5 min.  The cell pellet was 
suspended in Dulbecco’s modified eagles medium, supplemented with 80U/ml 
penicillin, 80U/ml streptomycin, 2mM L-glutamine and 10% (v/v) FBS.  The cell 
pellet from one rat liver was typically seeded into 4 6-well tissue culture plates, 
dependant upon size of cell pellet. The cell culture media was renewed every 
24 hours. 
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2.2.3. Culture of adherent cell lines 
MCF-7 and MDA cell lines were cultured as a monolayer and upon reaching 70-
80% confluence, were passaged. Cell culture media was aspirated from the 
cells and they were washed twice in sterile 1 x phosphate buffered saline (PBS 
- 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium 
chloride, pH 7.4, at 25 °C) (75cm 2 flask 10mls, 6 well plate 2ml/well) to remove 
any remaining culture media. Sufficient 1 x trypsin-EDTA solution, diluted in 1 x 
PBS was added to cover the cells (4mls per 75cm2 flask and 0.5ml/well of a 6 
well plate) for up to fifteen minutes under standard cell culture conditions. 
Careful impact to the cell culture vessel was used to encourage detachment.  
Once cells were sufficiently detached trypsin activity was inhibited by addition 
an equal volume of serum-supplemented culture media to the cell suspension. 
The cell suspension was removed to a 50ml Falcon tube and centrifuged at 
1500rpm for 5 minutes. The supernatant was discarded and the remaining cell 
pellet was re-suspended in fresh media. Cells were then seeded accordingly for 
cell maintenance or experimental protocols as described. 
2.2.4. Long-term storage of cells 
Cell stocks for all cell lines used were periodically frozen and stored long term in 
liquid nitrogen. Cells were detached, pelleted and suspended in freezing media 
(90% (v/v) FBS 10% (v/v) DMSO), typically 2mls per pellet from each confluent 
75cm2 tissue culture flask. The cell suspension was divided into sterile 
cryogenic storage vials (1.5ml/cryovial). Aliquots were frozen at a controlled rate 
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using an isopropyl alcohol filled freezing device (Mr Frosty™, Nalgene). Once 
cooled to -80°C, the cell stocks were transferred t o liquid nitrogen for long-term 
storage.  
2.2.5. Revival of cell stocks 
Cryogenically stored cell stocks were removed from liquid nitrogen and thawed 
at 37°C. The cell suspension was added to 10x its v olume of the appropriate 
cell culture media, pre warmed to 37°C in a 50ml fa lcon tube. The cells were 
pelleted by centrifugation for 5 minutes at 1500rpm and the supernatant was 
discarded. The cell pellet was re-suspended in fresh cell culture media and 
transferred to a cell culture flask. Viable cells were allowed 24 hours to attach 
before changing the culture media. Cells were then cultured as described 
previously. 
2.2.6. Assessment of cell viability and number 
For routine cell culture purposes, cell viability was assessed by the ability of a 
cell to exclude trypan blue. 100 µl of a cell suspension was added to an equal 
volume of 0.4% trypan blue solution and 200µl of fresh culture media  to give a 
final concentration of 0.1% (w/v) trypan blue. A small volume of the cell 
suspension was loaded onto a haemocytometer. Counts of both the total cell 
number and number of non- viable cells were performed in order to calculate 
the concentration of the cell suspension and the percentage viability.  
2.2.7. Charcoal/dextran treated foetal bovine serum 
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Foetal bovine serum naturally contains a variety of steroid hormones and other 
low molecular weight compounds, which may vary from one batch to the next.  
For investigations into steroid hormone signalling it is often necessary to culture 
cells with FBS that has been depleted of endogenous hormones to reduce the 
high background level of nuclear receptor activity.  This can be achieved by pre-
treating the serum with activated charcoal / dextran. 
20g of activated charcoal and 0.2g Dextran T70 (both from Sigma UK) were 
suspended in 250ml diH2O and incubated at room temperature for 10 min. The 
charcoal suspension was then centrifuged at 7000rpm for 15min at 4°C. The 
supernatant was then removed and the process repeated once more. The 
charcoal/dextran was then re-suspended in 200ml FBS in a conical flask and 
incubated at 55°C for 40 min with vigorous shaking.  The serum was then 
centrifuged at 10000rpm for 30min at 4°C.  The supe rnatant was retained and 
centrifuged again under the same conditions.  The media was the sterilised by 
passing through a 0.2µ filter unit. 
2.3. Cell Transfection 
2.3.1. Transfection using polyethylenimine 
MCF-7 cells were routinely transiently transfected using polyethylenimine (PEI) 
(from Polysciences inc).  Cells were seeded equally in 6 well tissue culture 
plates and allowed to grow to around 60-70% confluence, immediately before 
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transfection the cell culture media was removed and replaced with 1ml of fresh 
media per well of a 6 well plate.  
For a typical transfection in 1 well of a 6 well plate, 1.5µg of total plasmid DNA 
was placed in a centrifuge tube with 1ml of serum-free media. 10µl of 1mg/ml 
PEI solution in 20mM HEPES buffer (pH 7.5) was added and the solution was 
then vortex mixed for 10 seconds. The transfection master mix was then 
incubated for 30 min at room temperature before adding drop wise to the cell 
culture. Transfected cell cultures were incubated under standard conditions for 
24 hours before changing the culture media and proceeding with the 
investigation. 
2.3.2. Transfection using Effectene reagent 
MDA and H69 cells were transfected using Effectene transfection reagent. Cells 
were seeded into 6 well tissue culture plates and allowed to grow to 60-70% 
confluence. Immediately before transfection the cell culture media was removed 
and replaced with 1.5ml of fresh media. Typically one well of a 6 well plate was 
transfected with 1.5µg of total plasmid DNA. The plasmid DNA, buffer EC and 
enhancer solution were mixed to a ratio of 1µg DNA to 150µl EC and 10µl 
enhancer solution before being vortex mixed for 10 seconds and incubated at 
room temperature for 5 minutes. 15µl of Effectene solution was added per 1µg 
plasmid DNA, this was vortexed again and incubated at room temperature for 
20 minutes. The DNA/effectene transfection master mix was added to the 
Chapter 2 – Materials and Methods 
55 
cultures in a drop wise manner, the cells were then incubated for 24 hours 
under standard cell culture conditions. 
2.3.3. Transfection using GeneJuice transfection reagent 
Primary rat hepatocytes were routinely transfected using GeneJuice 
transfection reagent (from Novagen).  Following isolation, primary rat 
hepatocytes were seeded at a density of 7.5 x 105 cells per well of a 6 well 
plate. Typically 1.5µg of total plasmid DNA was transfected in each well of a 6 
well plate, a transfection master mix was made at a ratio of 100µl serum free 
culture media and 3µl GeneJuice transfection reagent to each 1µg of plasmid 
DNA. 
For each well of a 6 well plate to be transfected 150µl serum free culture media 
was added to 4.5µl of GeneJuice in a sterile tube and thoroughly mixed by 
vortexing before incubating for 5 min at room temperature. To this 1.5µg of total 
plasmid DNA was added and mixed by inverting several times.  The transfection 
master mix was added directly to the cells in culture media in a drop-wise 
manner.  Cells were then incubated for 24 hours. 
2.3.4. Assessment of transfection efficiency 
Cell cultures were transfected using the appropriate method as described 
previously with the green fluorescent protein expression plasmid peGFP-N1 
(eGFP). Cells were transfected for 24 hours before visualising by fluorescence 
microscopy, cells positive for eGFP were counted and expressed as a 
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percentage of the total number of cells per field of view. The average 
transfection efficiency of 3 fields of view was then calculated. (Fig 2.1) 
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Figure 2.1 - pEGFP-N1. A –pEGFP-N1 plasmid map. The basic plasmid map for 
pEGFP-N1 plasmid which encodes green fluorescent protein (GFP) used for 
transfection efficiency studies4. B – pEGFP-N1 transfected MCF-7 cells. Bright field 
and FITC images of GFP transfected MCF-7 estrogen responsive breast carcinoma 
cell culture. 
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2.4. Assay Systems 
2.4.1. Tetramethyrhodamine Methylester (TMRM) analysis of 
mitochondrial polarisation 
TMRM is a fluorescent dye which accumulates in polarised mitochondria of a 
cell. Excited TMRM emits in the red spectrum at 573nm (Fig 2.2A).Cells were 
seeded in 96 well imaging plates (Greiner) and cultured as previously 
described, before loading with TMRM (Sigma, UK) dissolved in DMSO. The 
concentration of TMRM was optimised for each individual cell type, The TMRM 
was added directly to the culture media before incubation for 1hr to allow 
uptake of the dye. After dye loading, the media was removed, cells were 
washed with sterile 37°C 1 x PBS and fresh, pre war med culture media was 
added.  The cells were then treated as required and the localisation of the 
TMRM was observed by imaging every 15 min using a high throughput 
automated imaging system. (Attovision Pathway, BD biosciences) The intensity 
of TMRM fluorescence was analysed using the Velocity imaging software (Fig 
2.2B) 
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Figure 2.2 – Trimethylrhodamine methylester. A.Excitation and emission of TMRM. 
Graph of the excitation and emission wavelengths of Trimethylrhodamine methylester 
(TMRM). B. TMRM loaded primary rat hepatocytes. Culture of primary rat hepatocytes 
loaded with 250µM TMRM, visualised on  the Attovision pathway imaging system. 
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2.4.2. MTS assay 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) is a tetrazolium compound which is used to measure 
mitochondrial reductase enzyme activity.  MTS undergoes reduction by NADPH   
the product of which is a soluble formazan product which is an indego colour 
and can be measured by absorbance at 490nm (Fig 2.3A). 
Cells were seeded in 96 well tissue culture plates and cultured as described 
previously. Following treatment, 10µl MTS reagent (CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay, Promega, UK) was added to each well. 
Cells were incubated for 2-4 hours before reading the absorbance at 490nm 
using a 96 well plate spectrophotometer (molecular devices spectraMAX 250). 
2.4.3. Dual-Glo reporter assay system 
For luciferase reporter gene assays, a dual reporter systems was used, this 
method is designed to increase experimental accuracy and limit experimental 
variability between replicates. The technique requires that two individual 
reporter enzymes, luciferase and renilla, are simultaneously expressed within a 
single system. The Dual-Glo assay system, obtained from Promega, exploits 
the luciferase activities of both firefly (Photinus pyralis) and renilla (Renilla 
reniformis, sea pansy) luciferase enzymes. Normally, firefly luciferase is 
expressed under the control of the target gene being studied.  A plasmid 
encoding the renilla under the control of a constantly active promoter is 
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simultaneously transfected.  A difference in the structure of the two luciferase 
enzymes allows the level of expression of each in a sample to be determined 
independently (Fig 2.3B,C). The level of firefly luciferase activity in the sample is 
first determined by addition of the substrate, luciferin.  The firefly luciferase 
reaction is then quenched and the renilla reaction is initiated simultaneously by 
the addition of the Stop and Glo substrate. 
Culture media was removed from transfected cells, which were then washed in 
1 x PBS before addition of 1 x passive lysis buffer to each well (150µl/well of 6 
well plate), lysis of the cells was encouraged by placing on an orbital shaking 
plate for 5 min. The Dual-Glo assay reagents were prepared in concordance 
with the manufacturers instructions. 100µl of the cell sample was added to an 
equal volume of luciferase substrate in a clear micro centrifuge tube and mixed 
by pipetting. The luciferase activity was then measured using a bench top 
luminometer. Firefly luciferase activity was then quenched by addition of 100µl 
Stop and Glo reagent. The activity of the renilla luciferase was then measured. 
In all experiments the relative luciferase of the experimental plasmid DNA 
construct (e.g. 3xERE luciferase) was normalised to the level of expression of 
the renilla luciferase levels by dividing the firefly measurement by the renilla 
value after subtraction of background luminescence. All values were then 
further normalised to the no treatment control and data expressed as a fold 
change in normalised luciferase activity in response to individual treatments.  
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Figure 2.3 – Assay systems. A. MTS reduction. Reaction diagram of the reduction of 
MTS to formazan as utilised by the Promega aqueous cell titre assay system. B. Firefly 
luciferase reaction. Reaction pathway of the conversion of Bettle luciferin to oxyluciferin 
catalysed by firefly luciferase. C. Renilla luciferase reasction Reaction pathway of the 
conversion of coelenterazine  to coelenteramide catalysed by Renilla luciferase. 
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2.4.4. Measurement of serum antifbody titre against pyruvate 
dehydrogenase (PDC) by ELISA 
Serum antibody activity against PDC was assessed by enzyme –linked 
immunosorbant assay (ELISA). The ELISA technique previously described by 
Jones et al95 is an established method for quantifying antibody binding to PDC. 
Wells of a microtitre plate were coated with 100µl of isolated murine PDC 
protein solution diluted to 5µg/ml in coating buffer (35mM NaHCO3, 15mM 
Na2CO3, pH 9.6) overnight at 4°C. Non-specific biding sit es were then blocked 
by incubation with 150µl/well PBSA (PBS + 5% (w/v) BSA) for 30min at 20°C.  
Following a wash step with  PBSTw (PBS + 0.05% (v/v) Tween 20), wells were 
incubated with mouse sample sera diluted 1:100 in PBSATw (PBS +0.05% (v/v) 
Tween 20 + 0.5% (w/v) BSA) for 3 hours at 20°C. The  plate was washed 3 
times before incubation with goat anti mouse IgG peroxidase-conjugated 
secondary antibody for 90min at 20°C. following one  further wash step, bound 
peroxidase activity was determined by addition of 100µl/well of developer 
(0.43mg/ml o-phenylenediamine (OPD), 0.012% (v/v) H2O2 in 0.1M citrate 
buffer (19.2g/L citric acid monohydrate in dH2O) for 15min before stopping the 
reaction with 100µl 2M H2SO4. Absorbance was read at 492nm on a plate 
reader. 
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2.5. Plasmid DNA Constructs  
2.5.1. Transformation of competent E.coli 
Plasmid DNA was synthesised via transformation and cloning of TOP10 
competent E.coli (Invitrogen). The bacterial cells were stored long term at -80°C 
and defrosted on ice before use. 50-100ng of plasmid DNA was introduced to 
10µl of TOP10 cell suspension, and incubated on ice for 30 minutes. The E.coli 
were then heat shocked by heating to 42°C for 30 se conds before removing to 
ice for a further 2 minutes.  250µl of sterile S.O.C media was then added and 
the culture was incubated in a orbital rotating incubator for 1 hour at 37°C. 5 
and 50µl of the transformed cells were then spread onto LB-agar plates 
containing the appropriate antibiotic selection markers for the plasmid 
(ampicillin 100µg/ml or kanamycin 50µg/ml). The plates were incubated for 8 
hours or overnight at 37°C, a single, well-defined colony was selected and used 
to inoculate 5mls of lysogeny broth (LB, Miller formulation – 10g tryptone, 5g 
yeast extract, 10g NaCl per litre) containing the appropriate antibiotic selection. 
Following overnight incubation the culture was subjected to plasmid mini prep 
protocol or used to inoculate a larger volume of LB, typically 100ml, for plasmid 
maxiprep purposes. 
2.5.2. Storage of transformed bacterial cultures 
Glycerol stocks were prepared for safe long-term storage of transformed 
bacterial cultures. 500µl of the LB culture was added to 500µl of a sterile 70:30 
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LB:glycerol mixture. The glycerol stock was immediately stored at -80°C. 
Glycerol stocks were used to produce more plasmid DNA when required, 20µl 
of the stock was streaked onto an LB-agar plate with the corresponding 
antibiotic selection marker and incubated at 37°C f or 8 hours or overnight. A 
single, defined colony was selected to grow the bacterial cultures as previously 
described. 
2.5.3. Plasmid DNA miniprep 
Plasmid purification by miniprep describes the alkaline lysis of bacterial cell 
walls followed by the isolation of plasmid DNA from the lysate by a process of 
binding and eluting the plasmid DNA to anion-exchange resin, and then eluting 
by washing with a high-salt buffer. Miniprep is designed for the purification of 
plasmid DNA from up to 5ml of a bacterial culture. Qiagen miniprep kits were 
used, following the manufacturers instructions. Briefly, 2mls of overnight culture 
was placed in a microcentrifuge tube, and the bacterial cells were pelleted by 
centrifugation at 10 000rpm for 1 minute, the supernatant was then discarded. 
The pellet was re-suspended in 250µl of buffer P1 (containing RNase), to which 
250µl of buffer P2 was added and mixed by numerous gentle inversions until 
complete lysis was achieved. Buffer N3 was added and mixed immediately by 
repeated inversions. The sample was then centrifuged at 13 000rpm for 10 
minutes to form a compact white pellet. The remaining supernatant was 
removed and added to a Qiaprep column, which was centrifuged for 60 
seconds.  The flow through was discarded and the column was washed by 
addition of 500µl of buffer PB and centrifuged once more. A final wash was 
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performed by addition of 750µl of buffer PE another 60 second centrifugation. 
All the wash buffers were discarded and the Qiaspin columns were centrifuged 
for a further 60 seconds to ensure complete removal of all PE buffer. The 
Qiaspin column was transferred to a sterile RNase-free microcentrifuge tube to 
collect the plasmid DNA. 50µl of sterile H2O was added to the column. A final 
centrifugation of the column at 13000 rpm for 60 seconds eluted the plasmid 
DNA.  
2.5.4. Plasmid DNA maxiprep 
Plasmid DNA maxiprep was performed using proprietary kits from Qiagen, 
following the manufacturers instructions. In brief, 100ml of a bacterial culture 
was centrifuged at 6000rpm for 20 minutes at 4°C to  pellet the cells. The 
supernatant was discarded before the bacterial pellet was re-suspend in 10ml 
of Buffer P1 (containing RNase), 10ml of buffer P2 was then added and mixed 
by repeated inversion. The suspension was incubated at room temperature for 
5 minutes before adding 10ml of chilled buffer P3 and mixing again by 
inversion. This mixture was incubated for 20 minutes on ice and then 
centrifuged again at 6000rpm for 20 minutes at 4°C. Following centrifugation, 
the supernatant was then applied to an equilibrated Qiagen-tip 500 column. 
Two 30ml washes of the column with buffer QC were performed and the flow 
through was discarded. 15ml of buffer QF was the applied to the column and 
the eluted plasmid was collected. The plasmid DNA was then precipitated by 
addition 10mls of 100% sterile isopropanol. The DNA was then pelleted by 
centrifugation at 6000rpm for 30 minutes at 4°C, th e supernatant was again 
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discarded. The DNA pellet was washed by resuspension in 5mls of sterile 70% 
EtOH and centrifuged for a further 10 minutes at 10 000rpm. The supernatant 
was removed and the pellet allowed to air dry before dissolving in an 
appropriate volume of nuclease free H2O. 
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2.6. Isolation and quantification of protein samples 
2.6.1. Isolation of protein from cell samples 
Culture media was removed from cell samples, which when were washed twice 
in 1 x PBS.  Cells were then detached by scraping into chilled 1 x PBS (1 ml per 
well of a 6 well plate), transferred to a sterile micro centrifuge tube and 
centrifuged at 13 000 rpm for 1 minute. The supernatant was discarded and the 
cell pellet was re-suspended in an appropriate volume of 20mM Tris buffer (pH 
7.4). Protein samples were stored long term at -80°C. 
2.6.2. Determination of protein concentration by Lowry protein assay 
The concentration of total protein in a sample was determined using the method 
first described by Lowry. Bovine serum albumin (BSA) was used to create 
standards of known protein concentration, creating a standard curve to which 
an unknown sample was compared. The complete Lowry buffer, termed buffer 
ABC was prepared immediately before the assay, it composed of 1 x Lowry A 
(2% w/v NaCO /4% w/v NaOH), B (2% w/v sodium tartrate) and C (1% w/v 
copper sulphate) mixed at a ratio of 100:1:1 (v:v:v) respectively.  
Bovine serum albumin (BSA) standards were prepared by serial dilution of a 
20µg/µl BSA stock, diluted in dH2O. 5ul of each standard or sample was placed 
in a micro centrifuge tube along with 50µl of dH2O and 1ml buffer ABC, the 
standards were then incubated at room temperature for 10 minutes before 
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addition of 100µl of Folins reagent (Fluka, UK) (pre-diluted 1:1 with dH2O). 
Samples were incubated at room temperature for a further 30 min before 
transferring to a disposable cuvette.  The absorbance of each sample at 750nm 
was determined by spectrophotometer. The absorbance of the standard 
concentration samples was used to create a standard curve. The equation of 
the standard curve was then used to determine the protein concentration of the 
unknown sample (Fig 2.4A,B). 
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Figure 2.4 – Lowry protein assay. A. Lowry standard curve. A typical standard curve 
created for the quantification of unknown protein sample concentrations. B. Lowry 
calculation. The equation devised from the standard curve (A) to determine the concentration 
of an unknown protein sample (x) from its absorption following Lowry assay (y). 
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2.7. SDS-page and western blotting 
2.7.1. SDS-page gel electrophoresis 
The separation of proteins within a sample by sodium dodecyl sulphate -
polyacrylamide gel electrophoresis (SDS-PAGE) is a commonly used method 
which was first described by in 1970 by Laemmli. SDS–PAGE allows the 
separation of proteins by their different molecular weight. The technique 
requires that the sample be heated in the presence of SDS and dithiothreitol 
(DTT) to completely denature the proteins, removing any quaternary, tertiary 
and secondary structures. The linearised proteins are associated with SDS, a 
negatively charged detergent. The samples are loaded onto a polyacrylamide 
gel matrix within an electric field, with the positive electrode at the opposite end 
of the gel to where the samples were loaded. Due to the negative charge of all 
proteins they migrate towards the positive electrode at a rate dependent on 
their molecular weight. 
The apparatus used for SDS-PAGE electrophoresis was the MINI-PROTEAN 
tetra cell, from Bio-Rad, UK. Gels were cast to a thickness of 0.75mm or 1mm, 
dependent on the volume of sample required.  Discontinuous gels were 
prepared by first casting a separating gel. 9-14% acrylamide gels were routinely 
used based on the molecular weight of the target protein. Separating gels were 
composed of 9-14% acrylamide, 375mM Tris buffer pH8.8, 0.1% w/v SDS, 
0.05% w/v ammonium persulphate and 0.05% v/v TEMED. Once the gels were 
cast, a layer of 100% isopropanol was applied to the surface of the gel to 
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achieve a sharp, level edge at the interface of the stacking and separating gels. 
Gels were left for 20-30 minutes to polymerise before removing the isopropanol 
and washing with distilled water. A 4% stacking gel, consisting of 4% w/v 
acrylamide, 125mM Tris buffer pH 6.8, 0.1% w/v SDS, 0.05% w/v ammonium 
persulphate and 0.1% (v/v) TEMED, was then cast on top of the separating gel. 
Wells for the samples were formed in the gel using combs placed into the 
stacking gel layer. The polymerised gels were secured in the electrophoresis 
tank, and submerged in electrophoresis running buffer (20mM Tris, 160mM 
glycine and 0.08% w/v SDS, pH 8.3).  
2.7.2. Sample preparation 
Protein sample concentration was determined by the Lowry method and 
routinely diluted to 2µg/µl with loading buffer (62.5mM Tris Buffer pH 6.8, 10% 
v/v glycerol, 2% w/v SDS 100mM DL-Dithiothreitol (DTT) and 0.02% w/v 
bromophenol blue). Samples were heated to 90°C for 3 min to linearise the 
protein, an appropriate amount of protein, dependent on the relative level of 
expression, was loaded to the gel, this was typically between 10-30µg of 
protein. An electric field of 100V was applied across the gel until a tight and 
uniform front was achieved at the gel interface, then 150V until the sample front 
reached the end of the gel. After this the gels were removed and the proteins 
were either stained or transferred to a nitrocellulose membrane for 
immunodetecton of specific proteins. 
2.7.3. Western blotting    
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Western blotting is the term used to describe the well-established technique of 
transferring the total protein from a polyacrylamide gel to a nitrocellulose 
membrane by electro-transfer. Polyacrylamide gels were equilibrated in transfer 
buffer (25mM Tris, 192 mM glycine and 20% v/v methanol, final pH 8.3) for 5 
minutes at 4°C. Gels were placed onto a piece of ni trocellulose membrane and 
assembled in a transfer cassette. The cassette was placed into the transfer tank 
and submerged in chilled transfer buffer.  Electro transfer was performed at 
100V for 2 hours on ice. The negatively charged proteins from the gel migrate 
towards the positive pole of the transfer tank and onto the positively charged 
nitrocellulose membrane.  
2.7.4. Immunodetection 
Following transfer, nitrocellulose membranes were blocked in a solution of 3% 
milk powder in 1 x TBS-T buffer (0.2M NaCl, 20mM Tris, pH 7.4 and 0.05% (v/v) 
tween 20) for 1 hour at room temperature or overnight at 4°C. The membranes 
were then washed three times in TBS-T for 5 minutes per wash. Nitrocellulose 
membranes were first incubated with an antibody specific for the target protein 
(primary antibody) for 1 hour at room temperature or overnight at 4°C. after 3 x 
5 min washes in TBS-T, a corresponding HRP-conjugated secondary antibody 
was applied and incubated as before. Antibodies were diluted in incubation 
buffer (0.3% (w/v) milk powder in TBS-T).  The secondary antibody was then 
discarded and the membranes were thoroughly washed for 30min in 1 x TBS-T 
with regular changes. The reagents, ECL, ECL-plus and ECL advance (GE 
healthcare, UK) for chemillumenescent detection HRP activity (corresponding to 
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target protein position and amount) on the membrane. The reagents were used 
according to the manufacturers instructions, Reagent 1 and 2 were mixed in 
equal volumes, applied evenly to the membrane and incubated for 30 seconds. 
Any excess reagent was removed and the membranes were sealed in catering 
wrap, ensuring the removal of any air. The membranes were then exposed to x-
ray film, which was then developed following standard procedure.  
2.8. Isolation and quantification nucleic acids 
2.8.1. TRIzol purification of RNA 
TRIzol reagent from Invitrogen was used to isolate RNA from whole tissue and 
cell samples. 1ml of TRIzol was added to each sample (sample not exceeding 
10% of volume of TRIzol) and the sample was disrupted by homogenising and 
sonication. The sample/TRIzol mixture was then removed to an RNase/DNase 
free 1.5ml micro centrifuge tube, 200µl of chloroform was added and mixed by 
vortexing. The sample was then centrifuged at 13000rpm in a bench-top 
microcentrifuge at 4°C for 15 min. The upper aqueou s layer was removed and 
placed into a clean micro centrifuge tube, to which 500µl of sterile isopropanol 
was added. The sample was then incubated on ice for 20 minutes.  Samples 
were then centrifuged again at 13000rpm for 15 minutes at 4°C.  The 
supernatant was discarded and the pellet dislodged in 70% ethanol before a 
final centrifugation (13000rpm, 15min, 4°C). The su pernatant was discarded 
and the pellet was allowed air dry before resuspension in an appropriate 
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volume of nuclease free H2O (typically 10-20µl). RNA samples were stored at–
80°C.  
2.8.2. Concentration, purity and integrity of nucleotides 
RNA concentration within a sample was determined by spectrophotometry. A 
small amount of the RNA sample was diluted in 1:100 in nuclease free H2O and 
transferred to a quartz cuvette. The absorbance of the sample was assessed at 
260nm, zeroed against pure nuclease free H2O. RNA concentration was then 
calculated, assuming an OD of 1.0 unit at 260nm being equivalent to 40µg/ml.  
Concentration of total dsDNA in a sample was calculated by spectrophotometry. 
DNA concentration can be estimated by measuring the absorbance at 260nm 
(A260), multiplying by the dilution factor, and using the relationship that an A260 
of 1.0 = 50µg/ml pure dsDNA.  
Purity of nucleotide samples and protein contamination was estimated from the 
A260/A280 ratio. An A260/A280 ratio between 1.7 and 2.0 generally represents a 
high-quality sample.  
 
DNA Purity (A260/A280) = A260 reading ÷ A280 reading 
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2.9. Reverse transcription- polymerase chain reaction (RT-
PCR) 
2.9.1. cDNA synthesis by reverse transcription 
First strand cDNA synthesis was performed using moloney murine leukaemia 
virus (MMLV) reverse transcriptase. MMLV reverse transcriptase is an RNA 
dependent DNA polymerase used for the efficient synthesis of cDNA from long 
RNA templates (Fig 2.5). The RNA sample was routinely diluted to a starting 
concentration of 200ng/µl with nuclease free H2O. 4µl of the RNA sample was 
incubated with 1µl of random primers (50ng/µl) (Promega) 90°C for 3 minutes.  
Samples were then placed on ice. A reverse transcription master mix consisting 
of 4µl x5 RT buffer (250mM Tris-HCl (pH 8.3 at 25°C), 375mM KCl, 15mM 
MgCl2, 50mM DTT), 8µl H20, 2µl of 10mM dNTP’s and 1µl of MMLV per sample 
was prepared on ice. 15µl of the master mix was added to each sample and 
gently mixed by pipetting, the samples were then incubated for 1 hour at 42°C 
to synthesise the cDNA. cDNA was stored at -20°C. 
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Figure 2.5 – Reverse transcription. Diagram showing the production of single stranded 
cDNA from mRNA template primed with oligo(dT) by reverse transcription catalysed by 
reverse transcriptase (RT). Reverse transcription can also be performed using random 
primers which can prime at various places along the transcript. 
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2.9.2. DNase treatment and removal of RNA  
Isolated RNA was treated with RQ1 RNase-free DNase (Promega, UK) to 
eliminate any possibility of contaminating genomic DNA being carried through to 
subsequent PCR based reactions. 0.1x the volume of RNA sample of both RQ1 
RNase free DNase and 10x DNase buffer were added to the RNA before 
incubation at 37°C for 30 min. Following this, 0.1x the volume of sample of 
DNase stop solution was added before a final incubation at 65°C for 10 min to 
inhibit the DNase activity. 
2.9.3. Polymerase chain reaction 
Polymerase chain reaction (PCR) is used to amplify specific DNA sequences, 
allowing for their detection. Taq polymerase (Taq) is a DNA polymerase named 
after the bacterium, Thermus aquaticus from which it was first isolated. Taq is 
routinely used in PCR for amplifying short segments of DNA (Fig 2.6). Taq 
operates at a optimum temperature range of 75-80°C,  and can replicate a 1000 
base pair strand of DNA in less than 10 seconds at 72°C, annealing 
temperatures around this range are normally used. It should be noted that Taq 
has a relatively low replication fidelity as it lacks 3' to 5' exonuclease 
proofreading activity, and has an error rate of about 1 in 9,000 nucleotides, for 
applications where a higher degree of accuracy is required, other DNA 
polymerases were used. A PCR master mix of 10µl 2x Go-Taq Green reagent, 
2 µl of each upstream and downstream primers (giving a final working primer 
concentration of 1µM) and 3µl of nuclease free H2O, per sample. 2µl (80ng) of 
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cDNA from each sample was added to a separate PCR microtube, to which 
18µl of the PCR master mix was added, mixing gently by pipetting. PCR 
reactions were performed in a programmable bench top thermocycler, and 
individual reaction conditions were optimised, a typical cycle was: 
Denature at 90°C for 3 min, 
35 cycles; 
Denature: 1 min at 90°C, 
Anneal: 1 min at optimised annealing temperature, 
Elongate: 1.5min at 73°C. 
Elongate: 8 min at 73°C. 
PCR products were stored at 4°C short term, or -80° C for longer periods. 
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Figure 2.6 – Polymerase chain reaction. Diagram showing the formation of multiple dsDNA 
copies of a section of a cDNA template from a previous reverse transcription reaction by 
polymerase chain reaction (PCR). 
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2.9.4. Primer Design 
Primer pairs for PCR were designed using the publically available tool, Primer 
BLAST (www.ncbi.nlm.nih.gov), where possible primers were designed to have 
a GC content in the region of 60% and have a length of approx 20 nucleotides. 
Melting temperature (Tm) was specified to be as close to 60°C as possible, 
ensuring the GC content of each primer is equal ensures both primers have 
similar Tm. The annealing temperature for each set of primer pairs was 
determined by an optimisation process, starting with a temperature 5°C below 
the specified Tm (55°C). 
2.9.5. Agarose gel electrophoresis 
Nucleic acids amplified by PCR were separated and identified, according to 
their length, by agarose gel electrophoresis. This method was used to separate 
different length nucleic acid acids based on their rate of migration across an 
agarose gel. The size of a nucleic acid fragment is inversely proportional to the 
rate at which it will migrate across a polymerised agarose gel towards the 
positive pole of an electrical field. Samples were compared against a DNA 
ladder made up from DNA fragments of known sizes. The percentage agarose 
content of the gel used was dependent upon the size of the target DNA 
fragment. Typically a target fragment of 150bp may be separated using a 1.5% 
(w/v) agarose gel. Agarose gels were prepared by adding the required mass of 
agarose powder (w/v) to 1 x tris-acetate-EDTA acid solution (TAE) (40mM 
tris, 20mM acetic acid, 1mM EDTA).  The mixture was then heated in a 
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microwave oven until completely melted. The gel solution was then allowed to 
cool to approximately 60°C before addition of ethid ium bromide (EtBr, final 
concentration 50µg/ml) and carefully mixing.  EtBr is a DNA intercalating agent, 
which once bound to DNA will fluoresce upon exposure to UV light. This allows 
nucleic acids to be visualised. The agarose gels were cast and sample wells 
were formed using a comb.  Once the gel was set and completely cooled it was 
positioned in an electrophoresis tank and submerged in 1 x TAE. PCR product 
samples mixed with 6x loading dye (New England Biolabs, UK) which increases 
their density so the sample sinks into the well, it also adds colour so the sample 
migration can be seen by eye. Samples were loaded alongside a DNA ladder 
standard of appropriate size (New England Biolabs, UK) to aid identification of 
PCR products Gels were typically run at 80V until sufficient migration was 
achieved, before visualisation under UV light. 
2.9.6. SYBR-Green quantitative RT-PCR (qRT-PCR) 
SYBR Green qRT-PCR is a method that allows for the relative expression of a 
particular gene to be quantitatively compared between different samples. qPCR 
is essentially very similar to standard PCR, with the addition of a dye, in this 
case SYBR-Green, once bound to double stranded DNA (dsDNA) will fluoresce. 
At the end of the elongation step of the PCR cycle, the level of fluorescence is 
detected as a measure of the amount of dsDNA present.  This is then used to 
determine the amount of transcript of the target gene present, relative to the 
other samples. Reaction conditions were optimised individually, and performed 
in a 13µl reaction volume. For each well of a 96 well PCR plate, 6.5 µl of 2x 
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SYBR Green Master Mix both upstream and downstream primers to a final 
concentration of 250nM and a sufficient volume of nuclease free H2O were 
combined to make a master mix. 13 µl of master mix was assed to each well of 
the plate. 10ng of each sample was added to individual wells before sealing the 
plate with optical film. The plates were then briefly centrifuged at 250g to collect 
all the contents at the bottom of each well.  qRT-PCR reactions were performed 
in an Applied Biosystems 7500 fast thermocycler. Gene expression was then 
calculated relative to control groups, and normalised against 18S ribosomal 
RNA to account for any variations.  Fold change in gene expression was 
calculated as 2(-ddCt) where ddCt is the change in Ct relative to 18s and 
experimental control (Fig 2.7). 
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Figure 2.7 – SYBR Green qRT-PCR. A. A screen print of a typical run method used on an 
ABI 7500 real time thermocyler, to perform SYBR Green quantitative RT-PCR. B. Diagram of 
the SYBR green qRT-PCR reaction, showing the SYBR green dye (green circles) binding to 
dsDNA and fluorescing. 
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Oligo ID 5'-3' sequence  (°C) Comments 
rAlbuminUS GTCAGAGGATGAAGTGCTC 57 
  
Willl amplify rat albumin 
(NM_134326.2) cDNA sequence 
of 471bp. 
  
rAlbuminDS TTAGCAAGTCTCAGCAGCAG 
rcMYCUS TCTCGGCCGCTGCCAAACTG 58 
  
Will amplify |NM_012603.2| 
Rattus norvegicus 
myelocytomatosis oncogene 
(Myc), cDNA  sequence of 204bp 
  
rcMYCDS TGGGCGAGCTGCTGTCGTTG 
rCK19US GCTGAAGCCTGGTACCTTACTCAGATT    53 
  
Will amplify rat CK19 cDNA 
sequence of 230 bp. 
  rCK19DS CTGATCACACCCTGGATGTGTGAC 
rERαUS AGTGAAGCCTCAATGATGGG 55 
  
Will amplify rat ESR1 cDNA 
sequence of 146 bp. 
  rERαDS ATCTCCAACCAGGCACACTC 
rERβUS AGGTGCTAATGGTGGGACTG 55 
  
Will amplify rat ESR2 cDNA 
sequence of 345 bp. 
  rERβDS ACTGCTGCTGGGAGGAGATA 
rKLF4US GGCGGGCTGATGGGCAAGTT 58 
  
Will amplify NM_053713.1| 
Rattus norvegicus Kruppel-like 
factor 4 (gut) (Klf4), cDNA 
sequence of 235bp 
  
rKLF4DS GCTGGGGTCCAGCGCTCAAG 
rOCT4US GGTGCAGGCCCGGAAGAGA   
58 
  
Will amplify NM_001009178.1| 
Rattus norvegicus POU class 5 
homeobox 1 (Pou5f1), cDNA 
sequence of 180bp 
  
rOCT4DS TCCCCTTCTGGCGCCGGTTA 
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rSOX2US CTTCCCGGAGGCTTGCTGGC 58 
  
Will amplify NM_001109181.1| 
Rattus norvegicus SRY (sex 
determining region Y)-box 2 
(Sox2), cDNA sequence of 105bp 
  
rSOX2DS CGCGTAGCTGTCCATGCGCT 
rSOX17US CAGCACATGCAGGACCATCCCA 52 
  
Will amplify rat (XM_001068621) 
cDNA sequence of 321bp. 
  rSOX17DS GTCCTGCTCCACGCCATCCAA 
rVimentinUS CGATGTGGACGTTTCCAAGCC 58 
  
Will amplify ref|NM_031140.1| 
Rattus norvegicus vimentin (Vim) 
cDNA sequence of 226bp 
  
rVimentinDS ATCCACTTCGCAGGTGAGTG 
hERαUS CCTGATGGCCAAGGCAGGCC 55 
  
Will amplify all 4 human  ERα 
variant transcripts  ( NM_000125; 
NM_001122740; NM_00112274 
and NM_001122742) cDNA 
sequences of 221bp. hERαDS TGGAGGGGCATCCGTGGAGG 
hERβUS AGCCCCGAGCAGCTAGTGCT 55 
  
Will amplify all 3 human  ERβ 
variant transcripts (variant 1, 
NM_001040275; variant 2, 
NM_001040276  and variant 3, 
NM_001437) cDNA sequences of 
249bp. 
hERβDS TGATGGGGCTGATGTGGCGC 
rmhGAPDHUS TGACATCAAGAAGGTGGTGAAG 55 Will amplify rat (NM_017008), 
human (NM_002046) or mouse 
(NM_008084)  glyceraldehyde 3 
phosphate dehydrogenase cDNA 
sequence of 243bp. rmhGAPDHDS2 TCTTACTCCTTGGAGGCCATGT 
rmh18sUS CCCGAAGCGTTTACTTTGAA 55 Will amplify cross species (rat, 
mouse, human) 18s cDNA 
sequence of  136 bp. 
rmh18SDS CCCTCTTAATCATGGCCTCA 
hTFF1US GTGCAAATAAGGGCTGCTGT 55 Will amplify human trefoil factor 1 
transcript (NM_003225) cDNA 
sequence of 177bp. 
hTFF1DS CCGAGCTCTGGGACTAATCA 
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m3a11US ACAAACAAGCAGGGATGGACCTGG 56 Will amplify NM_007818.3, Mus 
musculus cytochrome P450, 
family 3, subfamily a, polypeptide 
11 (Cyp3a11), cDNA sequence of 
152bp. m3a11DS AAATGGCAGAGGTTTGGGCCC 
mAbcb11US GTGGCCGTGCTCATCGCCTT 58 Will amplify mouse ATP-binding 
cassette, sub-family B 
(MDR/TAP), member 11 
(Abcb11) transcript 
(NM_021022.3) cDNA sequence 
of 201bp. 
mAbcb11DS TCCAATTCCAGCCACGGTGCG 
mAbcb1bUS TCCCGCAGTGGCTCTTGAAGC 58 Will amplify mouse ATP-binding 
cassette, sub-family B 
(MDR/TAP), member 1B 
(Abcb1b) (NM_011075.2) cDNA 
sequence of  150bp. mAbcb1bDS AACTCCATCACCACCTCACGTGC 
mAbcc1US GCAGCGCTGATGGCTCCGAT 60 Will amplify mouse ATP-binding 
cassette, sub-family C 
(CFTR/MRP), member 1 (Abcc1) 
transcript (NM_008576.2) cDNA 
sequence  of 174bp. mAbcc1DS TGTAGCCCCGGTCATGGCGA 
mAbcc2US CGGTGGACGACACACTCCCC   
60 
Will amplify mouse ATP-binding 
cassette, sub-family C 
(CFTR/MRP), member 2 (Abcc2) 
transcript (NM_013806.2) cDNA 
sequence of 182bp. mAbcc2DS CCGTCTCAGCTGGCGGGATG 
mAbcc3US CTGGCCCACGCGAGGAATGG 60 Will amplify mouse ATP-binding 
cassette, sub-family C 
(CFTR/MRP), member 3 (Abcc3 ) 
transcript (NM_029600.3) cDNA 
sequence of 184bp. mAbcc3DS TGCGGCCTCCAGGATTCGGA 
mAbcc4US GTTCCCGGAAGCCGCTGCTT 60 Will amplify all 3 variant of ATP-
binding cassette, sub-family C 
member 4 (Abcc4) transcripts 
(NM_001033336.3;NM_0011636
75.1andNM_001163676.1) cDNA 
sequences of 170bp. 
mAbcc4DS GCGAGCAGAGGTTGGCGTCC 
mAbcc5US AGCGCTGTACCAGGGCAACA 60 Will amplify both variant mouse 
ATP-binding cassette, sub-family 
C (CFTR/MRP), member 5 
(Abcc5) (variant 1, NM_013790.2 
and variant 2, NM_176839.1) 
cDNA sequences of 217bp. 
mAbcc5DS TGGTAGTGGTCCGGAAGGGCT 
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mAbcc6US GACCCGGTTGTGGATGGGCG 60 Will amplify mouse ATP-binding 
cassette, sub-family C 
(CFTR/MRP), member 6 (Abcc6) 
transcript (NM_018795.2) cDNA 
sequence of 216bp. mAbcc6DS CAGCAGGTTCCCGACTGGCG 
mIL1-βUS AAGCCTCGTGCTGTCGGACC 58 Will amplify NM_008361.3 Mus 
musculus interleukin 1 beta (Il1b), 
cDNA sequence of 201 bp. 
mIL-1βDS TCCAGCTGCAGGGTGGGTGT 
mERαUS AAGGGCAGTCACAATGAACC 54 
  
Will amplify mouse ESR1 cDNA 
sequence of 211 bp. 
  mERαDS GCCAGGTCATTCTCCACATT 
mERβUS GGGTGAAGGAGCTACTGCTG 55 
  
Will amplify mouse ESR2 cDNA 
sequence of  576 bp. 
  mERβDS GTGTCAGCTTCCGGCTACTC 
mSlc10a1US CCTGGCCTTTCCCCTAATGGCC 58 Will amplify mouse Slc10a1 
solute carrier family 10 
(sodium/bile acid cotransporter 
family), member 1 cDNA 
sequence of 164bp. mSlc10a1DS TGCCCTTCTGCCTCAGTTCATTGC 
 
 
Table 2.1 –PCR primer sequences. The designated name, 5’-3’ sequence, optimised 
annealing temperature (°C) and description of oligo nucleotides used as PCR primers.  
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2.10. Immuno-histochemistry and Immuno-cytochemistry 
2.10.1. Tissue preparation 
Tissue samples were fixed in a solution of 10% formalin 1 x PBS for 24 hours 
before processing. Tissue samples were processed following a standard 
protocol, which is a series of wash steps followed by dehydration in EtOH 
solutions. Tissue samples were embedded in paraffin wax and sections were 
cut (typically 5µm) and mounted onto slides. Sections were de-waxed in xylene 
and re-hydrated by a series of washes in ethanol solutions of decreasing 
concentration (absolute  90%  70%) and finally into deionised water.  
2.10.2. Proteinase K antigen retrieval 
Rehydrated tissue sectons were incubated in 10µg/ml proteinase K solution, 
diluted in 1xPBS for 25 min at 37°C. slides were th en rinsed thoroughly in  1 x 
PBS before continuing with immunostaining protocol.  
2.10.3. Sodium citrate antigen retrieval 
Rehydrated tissue sections were submerged in 0.01M sodium citrate buffer 
(pH6) and heated at full power in a microwave oven for 20 min, sections were 
allowed to cool to room temperature in the citrate buffer. 
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2.10.4. Immunostaining 
Tissue sections were incubated in 3% H2O2 solution at room temperature for 10 
min to block any endogenous peroxide activity. The sections were then washed 
for 5 min in 1 x PBS. Non-specific binding of the primary antibody was blocked 
by pre-incubating sections in 20% (v/v) FBS in 1 x PBS for 20 minutes. After 
blocking the primary antibody (diluted in 0.05% (v/v) FBS solution) was applied. 
Sufficient primary antibody was used so that the whole section was evenly 
covered, the sections were incubated for 1 hour at room temperature or 
overnight at 4°C. After incubation, sections were w ashed 3 times for 5 minutes 
in 1 x PBS, the appropriate HRP conjugated secondary antibody (diluted in 
0.05% (v/v) FCS in 1 x PBS) was then applied and incubated for 1 hour at room 
temperature. The sections were then washed a further 3 times for 5 minutes in 
1 x PBS.  The antibody binding activity was visualised using diaminobenzidine 
(DAB) chromogen (Dako, UK) to develop colour essentially as outlined in the 
manufacturer’s instructions. DAB incubation times were optimised for individual 
antibodies, but were typically between 30 seconds and 15 min. For each set of 
samples, control sections which were not incubated with a primary antibody 
were used, to control for non-specific binding of the secondary-HRP antibody 
had occurred. Following the DAB incubation step, sections were washed 
immediately in deionised water and counterstained with haematoxylin then 
washed in acidified water. The stained sections were dehydrated through 
sequential ethanol solutions of increasing concentration and finally into xylene.  
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The sections were then mounted in DPX mounting medium (Sigma, UK) and a 
cover slip was applied.  
2.10.5. Haematoxylin and eosin (H & E) staining  
For routine examination of tissue histology, sections were H and E stained. 
Haematoxylin is a blue stain that used to mark the nuclei and eosin is red dye 
that stains the cytoplasm.  Sections were de-waxed in xylene and then re-
hydrated sequentially through ethanol as described previously. Sections were 
then stained in haematoxylin for 1 minute before being thoroughly rinsed in 
water. The sections were then washed in acidified water for 5 seconds and 
washed once more in running water. The sections were then stained in eosin 
for 1 minute and washed in running water again. The sections were then 
dehydrated through ethanol washes and mounted in Depex.  
2.10.6. Sirius red staining 
Sirius red stain for collagen was performed by incubating dewaxed paraffin 
embedded sections in a 1g/L solution of Sirius red dye in saturated aqueous 
picric acid for 1 hour. Slides were then washed twice in acidified water (5ml 
glacial acetic acid in 1L dH2O before dehydration and mounting as described 
previously. 
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2.10.7. Immuno-cytochemistry   
The culture media was removed from samples of adherent cells in culture plates 
and the cells were washed twice in 1 x PBS. The cells were then fixed in situ 
with a fixative solution (2% v/v formaldehyde / 0.2% v/v glutaraldehyde in 1 x 
PBS pH 7.4) for 15 minutes at room temperature. The fixative was removed and 
cells were washed twice for 5 min in 1 x PBS.  The cell samples were blocked 
with a solution of 20% (v/v) FBS in 1 x PBS for 20 min at room temperature, to 
prevent non-specific protein binding. The blocking solution was removed before 
incubation for 1 hour with the primary antibody, diluted to the required 
concentration in antibody incubation buffer (0.05% (v/v) FCS in 1 x PBS). The 
samples were then washed twice for 5 min in 1 x PBS. The secondary antibody 
was then added, diluted to the required concentration in antibody incubation 
buffer and cells were incubated for 1 hour at room temperature (when using 
fluorescently labelled antibodies, the samples were shielded from light). After 
incubation, the secondary antibody was removed and cells were washed 4 
times in 1 x PBS for 5 min. Samples were then submerged in 1 x PBS and 
stored at 4°C before imaging. 
2.10.8. DAPI staining of DNA  
DAPI (4',6-diamidino-2-phenylindole) is fluorescent probe which is permeable to 
the cell membrane and is used to fluorescently stain cell nuclei. DAPI readily 
binds AT rich regions of dsDNA, and fluoresces at  a maximum of 461nm (blue). 
Following immunocytochemistry, DAPI was added to the cell samples at a 
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concentration of 6µg/ml and incubated for 10 minutes. Cells were then washed 
in 1 x PBS. 
  
Chapter 2 – Materials and Methods 
94 
Antigen Mwt (kDa) Dilution Comments and Source 
Albumin 60 1/200 ICC Rabbit polyclonal IgG. 
β-actin 44 1/4000 WB Mouse monoclonal IgG.  Chemicon  (MAB1501). 
CD3 23 1/100 IHC 
Rabbit polyclonal from Abcam.  
Sodium citrate antigen retrieval. 
CK-19 44 1/200 ICC Mouse monoclonal from Abcam.. 
ERα 68 
1/500 WB 
1/50 IHC, ICC 
Rabbit polyclonal from Abcam 
Proteinase K antigen retrieval. 
ERβ 55 
1/1000 WB 
1/100 IHC, ICC 
Rabbit polyclonal from Abcam 
Proteinase K antigen retrieval 
F4/80 102 1/100IHC 
Rabbit polyclonal from Abcam. 
Proteinase K antigen retrieval, ABC protocol. 
NIMP ~18 1/200 IHC 
Rat monoclonal from Abcam. 
Proteinase K antigen retrieval, ABC protocol 
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OV-6 56 1/100 ICC R & D biosciences, mouse monoclonal 
Vimentin 57 1/2000WB Rabbit monoclonal from chemicon 
  
Table 2.2 – Antibodies. The name, predicted molecular weight of detected peptide, dilution 
details and description of antibodies used for Western blot (WB), immunohistochemistry (IHC) 
and immnocytochemistry (ICC). 
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2.11. Calculation of half maximal effective concentration 
(EC50) and half maximal inhibitory concentration (IC50) 
Half maximal effective concentration (EC50) and the equivalent value for 
antagoist relationships, half maximal inhibitory concentration (IC50), are values 
which are often used to compare efficacy of different treatments in dose 
response experiments. When a dose response relationship forms a sigmoidal 
curve and the change in response to a treatment occurs rapidly over a limited 
number of concentrations, EC50 (or IC50) can be estimatated graphically. 
Using a non-computational method a semi-log plot is created from the dose 
response data, from this two different values can be obtained, Absolute EC50 
and relative EC50. Absolute EC50 describes 50% of the dynamic range of the 
assay system, whereas relative EC50 describes 50% of the activity of the test 
substance based on the experimental data. Whilst this non computational 
method for calculation of EC50 provides a good estimation, it may not provide a 
high level of accuracy as it is reliant upon constuction of a sigmoidal curve and 
the EC50 may fall between points on the log scale. 
To gain a higher degree of accuracy, EC50 can be calculated using statistical 
datafitting software which plots the data and by application of the hill 
cooefficient to calculate the slope of the sigmoidal curve, calculates an EC50 
value. 
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The Hill coefficient, widely used in biochemistry, refers to a value calculated for 
the slope of a sigmoidal curve formed in a dose response experiment, via 
application of the Hill equation.  The Hill equation was first devised by Archibald 
Vivian Hill in 1910 to calculate the cooperative binding of haemoglobin to O2. 
Free software available online at www.changebioscience.com was used for 
data fitting and calculation of EC50 and IC50 
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3. Chapter 3 – Results 
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3.1. Development of a screening system for transcriptional 
estrogenic activity  
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In order to identify xenobiotics that may estrogenic activity, a reliable 
screening method was developed.  An in vitro system by which a 
relatively large number of compounds could be tested for transcriptional 
estrogenic activity accurately and efficiently was required.  Using the 
estrogen responsive breast carcinoma cell line MCF-7, two separate 
methods were developed to measure estrogen receptor activation by 
xenobiotics. These were by luciferase reporter gene assay and by SYBR-
Green qRT-PCR analysis of the expression of the known estrogen 
responsive   gene, trefoil factor 1 (TFF1)96. 
3.1.1. Construction of an estrogen receptor luciferase reporter 
construct 
3.1.1.1. pGL3-Promoter vector 
The family of pGL3 luciferase reporter vectors provide a basis by which the 
regulation of mammalian gene expression can be quantitatively measured in 
vitro.  The pGL3 vector contains a large number of common restriction sites, 
which allows it to be modified by inserting custom DNA fragments alongside its 
modified firefly luciferase gene.  The pGL3-Promoter variant also has a SV40 
promoter upstream of the luciferase gene. 
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3.1.1.2. Estrogen response element insert 
A DNA fragment consisting of three repeats the consensus estrogen response 
element sequence (GGTCAnnnTGACC) was designed (3 x ERE), along with its 
complementary sequence. This fragment was flanked with sticky ends 
complementary to restriction sites of SacI and XhoI. These two restriction sites 
are found at positions 11 and 32 respectively of the pGL3-Promoter multiple 
cloning region, upstream of the SV40 promoter and luciferase gene, a 
schematic of the insert is shown in Fig 3.1A. 
3.1.1.3. Construction of a (ERE)3-Luciferase construct 
The pGL3-Promoter vector was linearised by digestion with SacI and XhoI, the 
digestion was confirmed by agarose gel electrophoresis, using undigested 
plasmid as a control.  The linearised plasmid was then separated from the small 
segment that lies between the two restriction sites, again by agarose gel 
electrophoresis, and purified. The 3xERE fragment was then ligated into the 
plasmid. 
To select a correctly constructed recombinant plasmid, numerous clones were 
screened by restriction digest with MluI.  The restriction site for this enzyme lies 
in the fragment of the cloning region which was removed, as it is not present in 
the (ERE)3 insert, clones which potentially contained the correct insert were 
identified. From the colonies selected, it was established that 3 clones were 
missing the MluI restriction site, colonies ♯2, 5 and 7. Fig 3.1B  
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These 3 clones were sent for DNA sequencing to ensure that the exact 
sequence had been inserted, and that it was orientated correctly.  The 
sequencing results revealed that both clones 5 and 7 were correctly assembled, 
but had a small number of differences in their sequence around the SacI and 
XhoI restriction sites Fig 3.1C. 
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Figure 3.1 – (ERE)3-pGL3-Luciferase construct. A. (ERE)3 DNA insert. Sequence of the 
concatamer of 3 estrogen response elements (ERE) used to create (ERE)3-pGL3-promoter-
luciferase reporter construct. B. Mlu restriction digest. Restriction digest screen for correctly 
assembled recombinant plasmids with (ERE)3 insert. C. (ERE)3-pGL3-promoter-luciferase 
DNA sequencing. Sequencing results of plasmid DNA prepared from colonies number 5 and 
7 showing the correctly assembled and orientated (ERE)3 insert. Note slight sequence 
difference upstream of insert between clones 5 and 7. 
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3.1.2. (ERE)3-Luciferase reporter construct is estrogen responsive 
To confirm the correct functioning of the newly developed constructs and to 
ascertain which was the most responsive, they were tested in the estrogen 
responsive breast carcinoma cell line, MCF-7.  In order to maximise reporter 
gene responsiveness to estrogens it is necessary to culture MCF-7 cells in 
medium supplemented with stripped serum to reduce the levels of estrogenic 
compounds within the culture (cell cultures which have undergone this process 
are termed ‘withdrawn’97). Expression of the ER was confirmed by RT-PCR and 
Western blot. Fig 3.2A demonstrates that the MCF-7 cell line expresses ERα 
mRNA under normal culture conditions and after 4 days of withdrawal.  This 
was confirmed by Western blot, it was apparent that the level of ERα protein 
increased following culture with stripped serum, relative to β-actin loading 
control. (Fig 3.2B) 
Purified plasmid DNA from both colonies 5 and 7 (termed ERLuc5 and ERLuc7 
respectively) were transiently transfected into MCF-7 cells, which were then 
treated for 24 hours with 10µM E2. Fig 3.2C demonstrates that untransfected 
MCF-7 cells had no luciferase activity, whereas cells transfected with the 
unmodified pGL3-Promoter vector exhibit a basal amount of luciferase activity 
which is driven by the promoter region and was unaffected by treatment with 
E2. MCF-7 transfected with either ERLuc5 or ERLuc7 exhibited a significant 
increase in luciferase activity over untransfected cultures.  
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Luciferase activity of MCF-7 cells transfected with either modified plasmid was 
significantly increased following treatment with E2 relative to DMSO vehicle 
control group. It was determined that ERLuc5 was the most responsive version 
of the construct and so was chosen for use in future investigations. 
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Figure 3.2 – MCF-7 dual luciferase assay. A. Confirmation of the expression of 
expression of hER in breast cancer cell lines by RT-PCR. Cells were cultured either in 
normal conditions or subjected to withdrawal for 4 days before isolation of RNA and RT-PCR 
using primer pairs specific for the human ER. PCR products were visualised by agarose gel 
electrophoresis and UV transillumination B. Confirmation of the expression of expression 
of hER in breast cancer cell lines by Western Blot. Cells were cultured either in normal 
conditions or subjected to withdrawal for 4 days before isolation of total protein and analysis 
by Western blot as described in chapter 2- materials and methods. 25µg of total protein/lane 
C.  (ERE)3-pGL3-promoter luciferase plasmid is estrogen responsive. MCF-7 cells were 
transiently transfected with (ERE)3-pGL3-promoter-luciferase variants and Renilla luciferase 
constructs before treatment with 10µM E2 or DMSO vehicle for 24 hours before analysis by 
dual-luciferase assay, expressed relative to Renilla luciferase. (Mean and SD of n=3).  
*=Significant increase over untransfected control, §/$= significant increase over unmodified 
pGL3-promoter, §§/$$=significant increase over DMSO vehicle. (p<0.05, Students t-test, two 
tailed). 
Chapter 3 - Results 
107 
3.1.3. (ERE)3-pGL3-Promoter construct (ERLuc5) is specific for 
estrogen receptors α and β 
In order to determine whether the (ERE)3-pGL3-promoter construct was specific 
for/preferentially transactivated by the ER, (ERE)3-pGL3-promoter activation 
was assessed in the non estrogen responsive breast carcinoma cell line MDA-
MB-231 (MDA) cell line. 
The expression of the ER in MDA cells was examined by RT-PCR and Western 
blot. ERα was not detected at either mRNA or protein levels, ERβ transcript was 
detected but no ERβ protein was observed (Fig 3.2A,B).  
MDA cells were transiently transfected with (ERE)3-pGL3-Promoter and pre 
treated with the pure estrogen receptor antagonist ICI182780. Figure 3.3A 
demonstrates that MDA cells transfected with (ERE)3-pGL3-Promoter do not 
respond to either E2 or ICI182780, suggesting that (ERE)3-pGL3-Promoter  was 
not transactivated, this is shown alongside a comparable investigation using the 
estrogen responsive MCF-7 cells, highlighting the difference in response.  
MDA cells were co-transfected with both (ERE)3-pGL3-Promoter and a range of 
expression constructs coding for the expression of a variety of nuclear 
receptors, or one which results in the expression of a green fluorescent protein 
(pEGFP-N1 or GFP). pEGFP-N1 is unrelated to steroid hormone signaling and 
was used as a control to show that any effects observed were not as a result of 
protein over expression.   
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Fig 3.3B shows that over expression of ERα in MDA cells resulted in the 
activation of (ERE)3-pGL3-Promoter by a  significant increase in luciferase 
activity over the cells transfected with pEGFP-N1. Treatment with 10nM E2 
resulted in a further increase in luciferase activity in cells expressing ERα or 
ERβ.  This shows that the (ERE)3-pGL3-Promoter vector is activated by the 
human ERα and ERβ and also that its luciferase expression is regulated in an 
estrogen dependent manner.   
No increase in luciferase activity was observed, nor was there a difference in 
activity following treatment with 10nM E2 over DMSO vehicle in MDA cells 
transfected with constructs coding for the expression of other nuclear receptors 
(androgen receptor (AR), testosterone receptor (TR), progesterone receptor 
(PR), glutocorticoid receptor (GR) and vitamin D receptor (VDR)).   
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Figure 3.3 – Specifity of (ERE)3-pGL3-promoter-luciferase A.MDA cells are not estrogen 
responsive. Cells were transiently transfected with (ERE)3-pGL3-promoter-luciferase and 
Renilla luciferase constructs before treatment for 24 hours with 10nM E2 or DMSO vehicle (+/- 
ICI182780). Luciferase activity was assessed by dual luciferase reporter assay and expressed 
relative to Renilla luciferase. (Mean and SD of n=3). *= Significantly different (p<0.05) to 
relevant control group (Students t-test, two tailed) B. (ERE)3-pGL3-promoter-luciferase 
construct Is specific for the ER. MDA cells were transiently transfected with plasmids 
coding for the expression of a range of different nuclear receptors, (ERE)3-pGL3-promoter-
luciferase and Renilla luciferase constructs before treatment for 24 hours with 10nM E2 or 
DMSO vehicle Luciferase activity was assessed by dual luciferase reporter assay and 
expressed relative to Renilla luciferase (Mean and SD of n=3). $ =Significant increase over 
GFP control group, *= significant increase over DMSO vehicle control group. (p<0.05, 
Students t-test, two tailed). 
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3.1.4. Estrogen mediated expression of trefoil factor 1. 
Trefoil factor 1 (TFF1) is a small cystine-rich protein that is regulated by the ER 
in estrogen responsive breast carcinoma cell lines, but not in estrogen receptor 
negative breast cancer cells. TFF1 expression in breast carcinoma cell lines is 
regulated primarily by estrogen signalling, mediated by the binding of an 
estrogen receptor-ligand complex to the consensus ERE, located 400bp 
upstream of the TFF1 transcription start site98.  Because TFF1 expression in 
MCF-7 cells is consistently up regulated by transcriptional estrogenic activity96, 
it was used to measure transcriptional estrogenic activity of estrogenic 
xenobiotics. 
3.1.4.1. TFF1 mRNA is expressed in MCF-7 cells 
Expression of TFF1 mRNA was confirmed in the cell lines MCF-7 and MDA by 
RT-PCR using primers designed to specifically amplify a section of the TFF1 
gene. Fig 3.4 A shows that TFF1 mRNA was detectable in MCF-7 by RT-PCR. 
3.1.4.2. Estrogen increases TFF1 expression is in MCF-7 but not MDA 
cell lines 
MCF-7 cells were cultured in culture media supplemented with charcoal-dextran 
treated FBS for a minimum of 4 days, after which they were treated with either 
DMSO vehicle or 10nM E2, a working concentration based on previous work by 
May et al96. Expression of TFF1 mRNA was assessed quantitatively by SYBR 
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Green qRT-PCR.  Following treatment with 10nM E2 a 3-fold increase in TFF1 
mRNA expression over DMSO vehicle was observed. 
Treatment with the ER antagonist ICI182780 at a concentration of 100nM 
caused a significant reduction in TFF1 expression in both DMSO and E2 
treatment groups, suggesting that even following a withdrawal process, 
estrogenic components persisted in the cell culture and an induced level of 
estrogenic activity remained in this MCF-7 cell model (Fig 3.4B). 
MDA cells are widely regarded as a classical estrogen non-responsive cell 
line99, and it is reported that non-estrogen responsive breast carcinoma cell 
lines do not express detectable TFF1 due to silencing by methylation of the non 
translated region -464 to +294 at the 5’ end of the TFF1 gene100. Fig 3.4A 
shows that in our hands a PCR product of the predicted size for TFF1 was 
detected in MDA cells, visualised at a lower intensity than in MCF-7. It is 
possible that at the point of RNA isolation TFF1 was expressed at a low level in 
our MDA cells.  No change in TFF1 mRNA expression was observed following 
treatment with either 10nM E2 or 100nM ICI182780 (Fig 3.4B). 
The expression of TFF1 following treatment was investigated by RT-PCR. Fig 
3.4C confirms shows that a single PCR product at the predicted size for TFF1 
was observed, which appears more abundant in the E2 treated cells. 
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Figure 3.4 – TFF1 induction in MCF-7. A. Confirmation of expression of TFF1 in MCF-7 
cells. Expression of TFF1 was confirmed by RT-PCR in MCF-7 and MDA cell lines using a 
primer pair designed to be specific for TFF1. PCR products were visualised by agarose gel 
electrophoresis and UV transillumination. B. Quantitative analysis of TFF1 mRNA 
expression. MCF-7 and MDA treated for 24 hours with 10nM E2 or DMSO +/- pre-treatment 
with ICI 182780 before analysis of TFF1 transcript levels by SYBR Green qRT-PCR (Mean 
and SD of n=3). *= significant increase over DMSO vehicle control group. ♯=significant 
decrease from no antagonist group.  (p<0.05, Students t-test, two tailed). C. Confirmation of 
TFF1 induction by E2 by RT-PCR. RT-PCR for TFF1 in MCF-7 cells following treatment for 
24 hours with 10nM E2 or DMSO vehicle. PCR products were visualised by agarose gel 
electrophoresis and UV transillumination. 
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A dose response curve of TFF1 gene induction in response to E2 at 
concentrations starting at 1pM, increasing sequentially by a factor of 10, up to a 
maximum of 1µM. A significant increase in TFF1 transcript over DMSO vehicle 
was observed at all concentrations, a peak response was identified at a 
concentration of 10nM (Fig 3.5A)   
3.1.4.3. Treatment with the anti-estrogen, tamoxifen, inhibits TFF1 
mRNA expression in MCF-7 cells 
To ensure that the increase in TFF1 gene expression seen was response to 
estrogen treatment and via the classical estrogen signalling pathway, cultures 
of MCF-7 cells were treated with increasing concentrations of the anti-
estrogenic drug, tamoxifen.  A dose response experiment was performed using 
concentrations of tamoxifen from 1pM up to a maximum of 1µM. MCF-7 cell 
cultures were treated with tamoxifen for 24hr, after which they were retreated 
with and also administered 10nM E2.  The expression of TFF1 mRNA, relative 
to DMSO vehicle was significantly decreased by administration of tamoxifen, 
with a maximal effect at a concentration of 100nM (Fig 3.5B). 
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Figure 3.5 – TFF1 expression dose-response. A. Dose-response curve of TFF1 
expression in response to E2. Expression of TFF1 in MCF-7 cells was quantified following 
treatment for 24 hours with increasing concentrations of E2 or DMSO before analysis of TFF1 
transcript levels by SYBR Green qRT-PCR (Mean and SD of n=3). B. Dose-response study 
of TFF1 inhibition by tamoxifen. Expression of TFF1 in MCF-7 cells was quantified following 
treatment for 24 hours with increasing concentrations of tamoxifen or DMSO before analysis 
of TFF1 transcript levels by SYBR Green qRT-PCR (Mean and SD of n=3). 
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3.1.5. Chapter 3.1 discussion 
A specific, accurate and reproducible means by which xenobiotics can be 
screened for transcriptional estrogenic activity was required. This was 
achieved by two means, a dual luciferase reporter system and by 
quantitative measurement of the well-known estrogen responsive gene, 
TFF1.  
A unique estrogen responsive luciferase reporter construct was 
developed which consists of 3 repeats of the consensus ERE controlling 
the expression of the luciferase gene. The transient transfection of this 
vector into MCF7 cells was optimized and its functionality and specificity 
for the ER were confirmed. Using the ERE-Luc5 construct and by 
quantification of TFF1 mRNA expression in MCF cells human estrogenic 
transcriptional activity can be confidently assessed. 
It was also determined that cell culture models have high levels of 
endogenous transcriptional estrogenic activity, which must be depleted in 
order to gain an accurate measurement of xenoestrogenic activity. 
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3.2. Screening for transcriptional estrogenic activity of 
xenobiotics  
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Using the construct and methodologies outlined in chapter 3.1, 
xenobiotics that have been proposed by others to be linked to the 
incidence of PBC were screened for transcriptional estrogenic activity.  
Examples include heavy metals and manufacturing by-products that may 
be found in industrial or mining areas and cosmetic/pharmaceutical 
preservatives and colouring agents. 
3.2.1. Screening for transcriptional estrogenic activity by dual 
luciferase assay. 
As described in chapter 3.1, a screening system for transcriptional estrogenic 
activity was developed using the estrogen responsive breast carcinoma cell line 
MCF-7 utilising a dual luciferase reporter assay system. 
Initially MCF-7 cells that were transiently transfected with the 3xERE-luciferase 
reporter construct were treated for 24 hours with either DMSO vehicle control or 
10µM of each compound. 
Figure 3.6A shows a number of compounds which were screened for 
xenoestrogenic activity, and were chosen based upon their possible ability to 
substitute lipoic acid upon PDC-E2.  2-octynoic acid, a compound frequently 
found in cosmetic products has previously been shown to have the potential to 
substitute lipoic acid on PDC-E2101, so 2-octynoic acid and a range of 
structurally similar compounds were examined.  The results show that although 
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some of these compounds may modulate ERα transcriptional activity, none of 
them acted as a direct ERα agonist and mainly inhibited reported gene activity. 
Exposure to certain pesticides, such as organophosphates, have been 
previously linked to some autoimmune conditions, although the mechanisms 
and long term effects are not well understood.  Considering that some 
pesticides have also been described as environmental xenoestrogens the group 
of compounds shown in fig 3.6B were considered potential candidates for 
initiating PBC. The results confirm the known estrogenic activity of 
methoxychlor, other compounds in this group either had no effect or were 
inhibitory upon reporter gene expression. 
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Figure 3.6 –Xenoestrogen screening 1. MCF-7 cells were transiently transfected with 
(ERE)3-pGL3-promoter-luciferase and Renilla luciferase constructs before treatment for 24 
hours with 10nM E2 or 10µM of a selected xenobiotic. Luciferase activity was assessed by 
dual luciferase reporter assay and expressed relative to Renilla luciferase. (Mean and SD of 
n=3). *= Significantly different (p<0.05) to DMSO control group (Students t-test, two tailed).  
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A selection of heavy metals, representing those which may be found  
contaminating the environment in industrial or mining areas were tested, the 
results are shown in fig 3.7A. None of these were found to increase ERα 
mediated gene expression, all of which were apparently inhibitory. 
Epidemiological studies have previously associated frequent use of certain 
cosmetic products with such as nail polish and hair colouring products with an 
increased incidence of PBC102. Fig 3.7B shows that some compounds which 
are commonly found in cosmetic products are human ERα agonists. Both butyl 
and propyl paraben which are both used as preservative agents in cosmetics, 
were transcriptional ERα agonists confirming the findings of Routledge et al103. 
In addition the cosmetic and food colouring agents sunset yellow (E110) and 
tartrazine (E102) were shown to increase ERα mediated reporter gene 
expression. 
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Figure 3.7 –Xenoestrogen screening 2. MCF-7 cells were transiently transfected with 
(ERE)3-pGL3-promoter-luciferase and Renilla luciferase constructs before treatment for 24 
hours with 10nM E2 or 10µM of a selected xenobiotic. Luciferase activity was assessed by 
dual luciferase reporter assay and expressed relative to Renilla luciferase. (Mean and SD of 
n=3). *= Significantly different (p<0.05) to DMSO control group (Students t-test, two tailed). 
Metal compounds were deloved into acid vehicle then diluted into cell culture media, an 
appropriate DMSO/metal vehicle combination was used as a control.  
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3.2.2. Xenobiotic mediated increase in luciferase activity is inhibited 
by ICI182780. 
Following the initial screening process, compounds that tested positive for ERα 
mediated transcriptional activity were repeated. In this investigation the MCF-7 
cells were also pre-treated with the pure estrogen receptor antagonist 
ICI182780 or vehicle control. This was performed to ensure the activity 
observed was mediated by ERα and not another transactivating nuclear 
receptor with affinity for the ERE.  Fig 3.8 illustrates how the 3xERE-luciferase 
mediated gene activity induced by sunset yellow, tartrazine, parabens and other 
compounds which initially tested positive was inhibited by the presence of 
ICI182780.  
Steroid hormones, other than estrogen, were also screened for estrogenic 
activity in our assay system. When administered at a concentration of 10µM 
many of these hormones increased ERα mediated gene transcription. Having 
already confirmed that the 3xERE-luciferase reporter construct is not activated 
by any other steroid hormone receptors, this result suggests that at high 
concentrations these other hormones can activate the ERα. 
Interestingly, the increase in ER mediated luciferase activity of some other 
forms of estrogen, ethinyl estradiol, estriol, estrone and equilin, and certain 
other steroid hormones was not decreased by ICI182780 in this investigation 
suggesting that this compound functions as a competitive agonist. 
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To examine this effect further, the same investigation was repeated at a lower 
and much more physiologically realistic treatment concentration of 10nM. In this 
study the increase in ERα mediated gene expression by the same set of steroid 
hormones was still observed, but the ERα mediated gene induction activity was 
comprehensively decreased by ICI182780 pre treatment (Fig 3.9). 
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Figure 3.8 –Antagonism of xenoestrogenic activity by ICI182780. MCF-7 cells were 
transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase constructs 
before treatment for 24 hours with 10nM E2 or 10µM of a selected xenobiotic (+/- 100nM 
ICI182780). Luciferase activity was assessed by dual luciferase reporter assay and expressed 
relative to Renilla luciferase. (Mean and SD of n=3). *= Significantly different (p<0.05) to 
DMSO control group (Students t-test, two tailed). 
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Figure 3.9 – Estrogenic activity of 10nM concentration of steroid hormones. MCF-7 cells 
were transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase 
constructs before treatment for 24 hours with 10nM concentration of various steroid hormones 
(+/- 100nM ICI182780). Luciferase activity was assessed by dual luciferase reporter assay 
and expressed relative to Renilla luciferase. (Mean and SD of n=3). *= Significantly different 
(p<0.05) to DMSO control group (Students t-test, two tailed). 
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3.2.3. Dose-response study of xenobiotic mediated transcriptional 
estrogenic activity. 
To investigate the potency of the xenoestrogens which were identified by the 
initial screening process, and to compare this activity to that of E2, dose 
response curves were constructed for the compounds of interest in the MCF-
7/3xERE-luciferase reporter assay.  
Typical dose-response curves for E2, tartrazine, sunset yellow, butyl paraben, 
propyl paraben and methoxychlor in MCF-7 cells are described in figs 3.10, 
3.11, 3.12.  In addition a typical dose response for the ER antagonist, 
ICI182780 is also shown. From these curves EC50 and IC50 values were 
calculated for the agonists and antagonist respectively (table 3.1). 
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Figure 3.10 - Dose response studies of xenoestrogen activity. A. E2. MCF-7 cells were 
transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase constructs 
before treatment for 24 hours with increasing concentrations  of E2. Luciferase activity was 
assessed by dual luciferase reporter assay and expressed relative to Renilla luciferase. (Mean 
and SD of n=3). * Denotes significant difference from lowest treatment concentration (p<0.05) 
(Tukey post hoc analysis) B. Sunset yellow. MCF-7 cells were transiently transfected with 
(ERE)3-pGL3-promoter-luciferase and Renilla luciferase constructs before treatment for 24 
hours with increasing concentrations of sunset yellow. Luciferase activity was assessed by 
dual luciferase reporter assay and expressed relative to Renilla luciferase. (Mean and SD of 
n=3). * Denotes significant difference from lowest treatment concentration (p<0.05) (Tukey 
post hoc analysis) 
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Figure 3.11 - Dose response studies of xenoestrogen activity. A. Tartrazine. MCF-7 cells 
were transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase 
constructs before treatment for 24 hours with increasing concentrations of Tartrazine. 
Luciferase activity was assessed by dual luciferase reporter assay and expressed relative to 
Renilla luciferase. (Mean and SD of n=3)). * Denotes significant difference from lowest 
treatment concentration (p<0.05)  (Tukey post hoc analysis) B. Butyl paraben. MCF-7 cells 
were transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase 
constructs before treatment for 24 hours with increasing concentrations of butyl paraben. 
Luciferase activity was assessed by dual luciferase reporter assay and expressed relative to 
Renilla luciferase. (Mean and SD of n=3).). * Denotes significant difference from lowest 
treatment concentration (p<0.05) (Tukey post hoc analysis) 
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Figure 3.12 - Dose response studies of xenoestrogen activity. A. Propyl paraben. MCF-7 
cells were transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase 
constructs before treatment for 24 hours with increasing concentrations  of propyl paraben. 
Luciferase activity was assessed by dual luciferase reporter assay and expressed relative to 
Renilla luciferase. (Mean and SD of n=3) * Denotes significant difference from lowest 
treatment concentration (p<0.05) (Tukey post hoc analysis)B. ICI 182780. MCF-7 cells were 
transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla luciferase constructs 
before treatment for 24 hours with increasing concentrations of ICI182780. Luciferase activity 
was assessed by dual luciferase reporter assay and expressed relative to Renilla luciferase. 
(Mean and SD of n=3).* Denotes significant difference from lowest treatment concentration 
(p<0.05) (Tukey post hoc analysis) 
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Table 3.1 – Xenoestrogen EC50 values. Calculated EC50/IC50 values from dose response 
experiments, figs 3.10, 3.11, 3.12. 
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These data suggest that the food and cosmetic colouring agents tartrazine and 
sunset yellow are in the region of 50 times less effective at activating the human 
ER than E2, whilst the parabens and methoxychlor were less potent still.  This 
implies that a much higher concentration or level of exposure to these 
compounds would be required to produce a similar level of transcriptional 
activity to that of E2. 
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3.2.4. Screening for transcriptional estrogenic activity by 
measurement of TFF1 expression in MCF-7 cells 
The effects upon ER mediated transcription observed by dual luciferase assay 
were confirmed using an alternative measurement of estrogenic activity in the 
same cell line.  The relative induction in expression of TFF1 mRNA in MCF-7 
cells was measured (as described in the previous chapter) in response to 
treatment with the xenoestrogens which were identified through their effects 
upon 3xERE-pGl3 reporter activity.  The investigation was again conducted +/- 
ICI182780 pre-treatment.  In this assay the same compounds which had 
induced 3xERE-pGL3 reporter gene activity also significantly increased the 
level of TFF1 transcription over that of the vehicle control.  The action of the ER 
antagonist ICI182780 was also parallel to the previous investigation, inhibiting 
increased TFF1 expression in a similar manner (Fig 3.13). 
The effects of high concentrations (10µM) of certain steroid hormones namely 
progesterone, testosterone and other forms of estrogen were concordant with 
the findings of the dual luciferase reporter assay screen.  10µM concentrations 
of both testosterone and progesterone significantly increased TFF1 mRNA 
expression over vehicle controls. Equally pre treatment with ICI182780 did not 
significantly reduce the TFF1 gene induction caused by administration of high 
concentration of the estrogen analogues estrone, ethinyl estradiol and estriol. 
As before, the investigation was repeated at a more physiologically realistic 
concentration of 10nM, Fig 3.14 details the findings of this study. In line with the 
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data obtained by luciferase reporter assay, only estrogens increased TFF1 
mRNA expression at 10nM concentrations, and in all cases TFF1 induction was 
inhibited by pre treatment with ICI182780. 
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Figure 3.13 – Xenoestrogen mediated TFF1 induction. Expression of TFF1 in MCF-7 cells 
was quantified by SYBR Green qRT-PCR following treatment for 24 hours with 10nM E2, 
10µM xenobiotics or DMSO vehicle  (+/- pre-treatment with 100nM ICI182790) before analysis 
of TFF1 transcript levels by SYBR Green qRT-PCR *= significant increase over DMSO vehicle 
control group (p<0.05) (Students t-test, two tailed) Data are mean and SD of n=3. 
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Figure 3.14 – Expression of TFF1 following treatment with 10nM steroid hormones. 
Expression of TFF1 in MCF-7 cells was quantified by SYBR Green qRT-PCR following 
treatment for 24 hours with increasing 10nM concentration of various steroid hormones or 
DMSO vehicle (+/- pre-treatment with 100nM ICI182790). TFF1 transcript levels were 
quantified by SYBR Green qRT-PCR *= significant increase over DMSO vehicle control group 
(p<0.05) (Students t-test, two tailed) Data are mean and SD of n=3.  
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3.2.5. Screening for transcriptional xenoestrogenic activity in primary 
rat hepatocytes by dual luciferase reporter assay. 
Since we are interested in the potential estrogenic effects of xenobiotics on the 
liver the estrogenic activity of a range of xenobiotics was examined in cultures 
of primary rat hepatocytes. 
Expression of both ERα and ERβ mRNA was examined by RT-PCR. ERα 
transcript was detectable in whole liver (very low expression) and in 
hepatocytes at t=0, 48 and 72 hours. ERα was detected in quiescent and 
activated hepatic stellate cell cultures and also in the pancreatic progenitor cell 
line b13 in both its normal state and in its hepatocyte like phenotype termed 
b13/h104. ERβ mRNA was detected in all of the samples, with the exception of 
activated hepatic stellate cells.  These results were confirmed by Western 
blotting. (Fig3.15) 
Compounds were chosen as before, based on their presence in products or 
specific localized environments that have been linked to PBC through previous 
epidemiological studies. Individual or groups of compounds which were 
inhibitory in the MCF-7 model were omitted from this process. 
Cultures of primary rat hepatocytes were transfected with 3xERE-luciferase 
reporter construct as previously described and treated with 10µM concentration 
of the chosen compounds for a period of 24 hours. The luciferase activity was 
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normalised to Renilla luciferase and expressed as a percentage of DMSO 
vehicle control, the results are shown in fig  3.16. 
In rat hepatocytes neither 10nM or 10µM E2 significantly increased ER 
mediated luciferase activity over DMSO vehicle.  In contrast ethinyl estradiol 
(EE) significantly increased luciferase activity in this assay.  Of the xenobiotics 
examined, methyl, propyl and benzyl paraben, sodium benzoate, sunset yellow, 
and tartrazine all tested positive for increased ER mediated transcriptional 
luciferase activity. In addition genistein, a known phytoestrogen increased ER 
mediated transcriptional luciferase activity over the control group. 
2-octynoic acid, a common cosmetic and food additive did not cause any 
increase in luciferase activity, nor did any other structurally similar compounds. 
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Figure 3.15 – Expression of the rat ER. A. Confirmation of the expression of the ER in 
rat liver cells by RT-PCR. Cells were cultured under normal conditions before isolation of 
RNA and RT-PCR using primers specific for the rat ER. PCR products were visualised by 
agarose gel electrophoresis and UV transillumination B. Confirmation of the expression of 
the ER in rat liver cells by Western blot. Cells were cultured under normal conditions days 
before isolation of total protein and analysis by Western blot as described in materials and 
methods. 25µg of total protein/lane. 
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Figure 3.16 –Xenoestrogen screening in primary rat hepatocytes. Primary rat hepatocytes 
were transiently transfected with (ERE)3-pGL3-promoter-luciferase and Renilla constructs 
before treatment for 24 hours with 10nM E2 or 10µM of a selected xenobiotic. Luciferase 
activity was assessed by dual luciferase reporter assay and expressed relative to Renilla 
luciferase. (Mean and SD of n=3). *= Significantly different (p<0.05) to DMSO control group 
(Students t-test, two tailed). 
Chapter 3 - Results 
140 
3.2.6. (ERE)3-pGL3-Promoter is responsive to both ERα and ERβ. 
Since there are two different known ER genes, ERα and ERβ, 2 ER null cell 
lines, MDA and the human cholangiocyte cell line H69, were used to establish 
whether (ERE)3pGL3-Promoter is responsive to both ER types. 
Cultures of MDA cells were transfected with a plasmid directing the expression 
of human ERα, along with (ERE)3-pGL3-promoter and RL-TK before treatment 
with previously identified xenoestrogens. Fig 3.17A shows that treatment with 
both tartrazine and methoxychlor caused a significant increase in ERα mediated 
luciferase expression. Sunset yellow did not cause a change in ERα 
transcriptional activity in this model.  In all cases pre treatment with the estrogen 
receptor antagonist ICI 182780 resulted in a significant decrease in ERE-
luciferase activity. 
A parallel investigation was performed, replacing the ERα expression vector 
with one coding for ERβ. In this study, both sunset yellow and tartrazine caused 
a significant increase in reporter gene activity, similar to that of 10nM E2.  
Again, in all cases this activity was attenuated by administration of ICI 182780. 
Fig 3.17B 
The H69 cell line is a stabilised human cholangiocyte cell line that does not 
express either a functional ERα or ERβ.  This cell line was transfected with 
plasmids directing either ERα or ERβ, in a similar investigation to the previous 
study performed using the MDA model.  Fig 3.18 demonstrates that in the H69 
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cell line 10nM E2 caused a significant increase in reporter gene expression, 
through activation of both ERα and ERβ.  Treatment with 10µM tartrazine also 
activated both estrogen receptor variants, but showed a much greater affinity for 
ERβ subtype. Concordant with the findings in the MDA cell model, sunset 
yellow did not activate ERα in H69, but did significantly increase ERβ mediated 
reporter gene activity, albeit with seeming low potency in comparison to E2 and 
tartrazine.  
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Figure 3.17 – Ectopic expression and activation of the hER in MDA cells . A. ERα. Non 
estrogen responsive MDA cells were transiently transfected with a plasmid coding for A. ERα 
or B. ERβ, (ERE)3-pGL3-promoter-luciferase and Renilla constructs before treatment for 24 
hours with 10nM E2 or 10µM selected xenobiotic (+/- 100nM ICI182780). Luciferase activity 
was assessed by dual luciferase reporter assay and expressed relative to Renilla luciferase. 
(Mean and SD of n=3). *= Significantly different to DMSO control group, **=significantly 
decrease over no antagonist group (p<0.05) (Students t-test, two tailed).  
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Figure 3.18 – Ectopic expression and activation of the hER in H69 cells . Non estrogen 
responsive H69 cells were transiently transfected with a plasmid coding for ERα or ERβ , 
(ERE)3-pGL3-promoter-luciferase construct and Renilla before treatment for 24 hours with 
10nM E2 or 10µM selected xenobiotic. Luciferase activity was assessed by dual luciferase 
reporter assay and expressed relative to Renilla luciferase. (Mean and SD of n=3). *= 
Significantly different (p<0.05) to DMSO control group (Students t-test, two tailed).  
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3.2.7. Chapter 3.2 discussion 
The specific aim of this series of investigations was to confirm that 
identified xenobiotics have transcriptional estrogenic activity. 
Compounds were initially screened for estrogenic activity utilizing the 
luciferase reporter assay developed in chapter 3.1 and by measuring TFF1 
mRNA expression in the estrogen responsive breast carcinoma cell line 
MCF-7.  Using these methods a variety of xenoestrogens were identified, 
most notably butyl paraben, propyl paraben, sunset yellow and tartrazine.  
When this assay system was applied to primary rat hepatocytes the 
results were similar to those in the MCF-7 model, there were however, a 
few prominent differences.  In hepatocytes E2 did not significantly 
increase activity, possibly due to the metabolic activity of hepatocytes 
rapidly deactivating E2.  This is supported by the increase in luciferase 
reporter activity following treatment with EE, an estrogen variant which is 
known to be more resistant to hepatic metabolism85, 86.  Similarly, some 
forms of the group of parabens compounds which were active in MCF-7 
were not active in hepatocyte cultures and vice versa. 
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3.3. Effect of xenoestrogen exposure on mitochondrial 
function and polarisation 
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The potential for a xenoestrogen exposure to be a initiating or risk factor 
for the development of PBC may be dependant upon it also being toxic to 
liver cells, potentially via interaction with mitochondria.  This may be 
either through conjugation to PDC enzyme subunits or through another 
mechanism(s).  These effects may result in loss of mitochondrial function 
or polarisation and development of AMA. 
This chapter describes the ways in which previously identified 
xenoestrogens were screened for mitochondrial toxicity. 
3.3.1. Mitochondrial reductase activity in primary rat hepatocytes in 
response to xenoestrogen exposure. 
Cultures of primary rat hepatocytes were treated for 24 hours with a range of 
compounds which were selected based on their estrogenic activity identified in 
the previous chapter. Figure 3.19 shows that at a concentration of 10µM, none 
of the xenoestrogenic compounds selected caused a significant decrease in 
mitochondrial reductase enzyme activity.  In contrast, the vitamin K precursor, 
menadione, known for its effects on mitochondrial function and polarisation 
through interference with mitochondrial Calcium homeostasis105, significantly 
decreased MTS reduction in rat hepatocytes at a final treatment concentration 
of 200µM. Treatment with both 10µM E2 and EE resulted in a significant 
increase in mitochondrial reductase activity over DMSO vehicle group. 
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Figure 3.19 –MTS activity in primary rat hepatocytes following xenoestrogen exposure 
Cultures of primary rat hepatocytes were treated for 24 hours with selected compounds at a 
concentration of 10µM or 200µM menadione as a positive control .Mitochondrial reductase 
activity was assessed by MTS assay  (Mean and SD of n=8). *= Significant increase, 
**=significant decrease, over DMSO control. (p<0.05) (Students t-test, two tailed).  
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Menadione is commonly used to model mitochondrial depolarisation at a final 
treatment concentration of 200µM, it is possible that high concentrations of 
xenobiotics may be required to produce similar effects in an in vitro model. To 
investigate this, dose-studies were performed for the food and cosmetic 
colouring agents tartrazine and sunset yellow.   
Fig 3.20 shows that after 24 hours treatment, reduction of MTS by mitochondrial 
reductase enzymes in primary rat hepatocytes was significantly decreased by 
sunset yellow at concentrations of 1mM and 100µM, suggesting that under 
these conditions the concentration of sunset yellow required to produce a 
negative effect on mitochondrial reductase activity lies between 100 and 10µM. 
After 48 hours treatment,  1mM sunset yellow resulted in a significant decrease 
in mitochondrial reductase function, suggesting that there is either a degree of 
recovery from the sunset yellow insult, or that the metabolic activity of primary 
hepatocytes results in breakdown and detoxification of the sunset yellow 
compound. 
The MTS reduction by primary rat hepatocytes treated with varying 
concentrations of tartrazine after 48 hours is shown in Fig 3.21. In this 
investigation, none of the treatment concentrations of tartrazine resulted in any 
significant decrease in MTS reduction, relative to DMSO vehicle control. 
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Figure 3.20 –Dose response study of MTS reduction in primary rat hepatocytes treated 
with sunset yellow A. Cultures of primary rat hepatocytes were treated for 24 hours with 
increasing concentrations of sunset yellow or 200µM menadione as a positive control. 
Mitochondrial reductase activity was assessed by MTS assay (Mean and SD of n=12). *= 
Significantly different to DMSO control. (p<0.05) (Students t-test, two tailed). B. Cultures of 
primary rat hepatocytes were treated for 48 hours with increasing concentrations of sunset 
yellow or 200µM menadione as a positive control .Mitochondrial reductase activity was 
assessed by MTS assay (Mean and SD of n=12). *= Significantly different to DMSO control. 
(p<0.05) (Students t-test, two tailed). 
Chapter 3 - Results 
150 
Figure 3.21 –Dose response study of MTS reduction in primary rat hepatocytes treated 
with tartrazine. Cultures of primary rat hepatocytes were treated for 24 hours with increasing 
concentrations of tartrazine or 200µM menadione as a positive control. Mitochondrial 
reductase activity was assessed by MTS assay. (Mean and SD of n=12). *= Significantly 
different to DMSO control. (p<0.05) (Students t-test, two tailed).  
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In an attempt to identify the mechanism by which sunset yellow causes loss of 
mitochondrial reductase enzyme activity in rat hepatocytes.  Cultures of primary 
hepatocytes were treated with 200µM sunset yellow, alongside a variety of 
different compounds which are known to influence mitochondrial functionality 
and also a selection of caspase inhibitors. 
Fig 3.22 demonstrates that 200µM sunset yellow results in a significant 
decrease in MTS reduction in primary rat hepatocytes as described previously.  
Treatment of hepatocytes with 2µM bongkrekic acid also resulted in a reduction 
in MTS reduction.  Administration of caspase 3, 4 and 9 inhibitors all resulted in 
a significant increase in MTS reduction over DMSO vehicle control. This may be 
a result of increased viability of deteriorating primary hepatocyte cultures by 
inhibition of apoptosis by selected caspase inhibitors. 
Co-treatment of hepatocyte cultures with 200µM sunset yellow 1µM and the 
reducing agent dithiothreitol (DTT) or bongkrekic acid caused an exacerbation 
of the effect of treatment with sunset yellow alone. Caspase 3 and 4 inhibitors 
again caused an increase in MTS reduction, but the positive effect of caspase 9 
inhibitor was lost.  Treatment of rat hepatocytes with high concentration D-
glucose caused a reduction in the loss of mitochondrial reductase activity 
produced by sunset yellow. 
In this investigation a reduction in enzyme activitywas observed, it may be that 
this is caused by a reduction in mitochondrial viability, but it may also be 
accounted to a reduction in cell number and therefore the number of 
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mitochondria present, caused by either cell death or reduced proliferation. 
Without performing a corresponding protein assay this is difficult to determine. 
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Figure 3.22 – Effects of modulators of mitochondrial function on MTS reduction in 
primary rat hepatocytes following treatment with sunset yellow. Cultures of primary rat 
hepatocytes were treated for 24 hours a variety of compounds known to affect mitochondrial 
function, +/- 200µM sunset yellow. 200µM menadione was used as a positive control 
Mitochondrial reductase activity was assessed by MTS assay. (Mean and SD of n=8). *= 
Significantly increase, **=significant decrease over DMSO control (p<0.05) (Students t-test, 
two tailed).  
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3.3.2. Measurement of mitochondrial polarisation in rat hepatocytes 
by live TMRM localisation following exposure to xenoestrogens 
Mitochondrial functionality and viability in response to treatment with 
xenoestrogens was also assed by live imaging of TMRM localisation in primary 
rat hepatocytes. TMRM is sequestered within mitochondria relative to the 
potential across the mitochondrial membrane. 
Cultures of primary hepatocytes were pre loaded with TMRM before treatment 
with xenoestrogens or controls. Fig 3.23 details the mean intensity of 
fluorescence at the emission wavelength of TMRM (574nm) per field of view, 
following treatment. Intensity of fluorescence was measured at 40 time points of 
15-minute intervals. It shows that some compounds, sodium benzoate, 
tartrazine and sunset yellow cause a loss of mitochondrial membrane potential, 
similar to the effect of menadione.  
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Figure 3.23 –TMRM intensity in primary rat hepatocytes following treatment with 
xenobiotics. Cultures of primary rat hepatocytes were loaded with 250µM TMRM before 
treatment with 10µM xenoestrogens or 200µM menadione as a positive control. Mean 
fluorescence was assessed by imaging on the Attovision Pathaway (BD Biosciences) every 
15min. Measurement of mean intensity per field of view was performed using Velocity image 
analysis software. (Mean and SD of n=8). Red box = significant decrease in intensity from 
DMSO control (p<0.05) (Students t-test, two tailed).  
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3.3.3. Chapter 3.3 discussion. 
The aim of this section was to identify which, if any, of the previously 
discovered xenoestrogens have an effect on heptocyte mitochondrial 
function, viability or polarisation.  Compounds were screened by both 
MTS assay as a measure of mitochondrial reductase enzyme functionality, 
and by live imaging of TMRM localisation to measure mitochondrial 
membrane potential. 
The MTS assay revealed that treatment with sunset yellow caused a 
decrease in mitochondrial reductase activity in primary rat hepatocytes. 
This effect of sunset yellow was exaggerated upon administration of DTT 
and decreased by treatment with high concentration D-glucose.  This may 
imply that the effects of sunset yellow are upon, or intrinsically linked, 
with components of the electron transport chain or another aspect of 
mitochondrial energetics.  It may also suggest that either sunset yellow is 
a more potent mitochondrial toxin upon being reduced by DTT. Sunset 
yellow is known to be susceptible to reduction, and its major route of 
metabolism is reduction via intestinal bacteria, an action which is known 
to be inhibited by high glucose concentrations106, 107 
The screening system developed to measure changes in mitochondrial 
polarisation by imaging of TMRM localisation revealed that sodium 
benzoate, tartrazine and sunset yellow all caused a reduction in 
membrane potential after 2 hours of treatment. 
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These results intimate that the food and cosmetic additives sunset yellow 
and tartrazine, both of which were also shown to activate the human 
estrogen receptor, may have damaging effects on mitochondrial function. 
However, without performing corresponding assays to determine cell 
number, it is not possible to say whether these effects may be attributed 
to loss of cell viability or reduced proliferation following treatment. 
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3.4.  in vivo exposure to xenoestrogens  
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 The effects of exposure to estrogen, and xenoestrogens identified in the 
previous chapters, upon the liver were investigated using a variety of in 
vivo models. 
The effect of estrogen exposure upon liver has previously been 
documented; it is known that administration of estrogen to the mouse 
results in a cholestatic condition, and altered expression of bile salt 
transport proteins, the two factors possibly being intrinsically linked108. 
The aims of this component of the project were to investigate further 
these effects of estrogen, and compare them to the effects of the 
xenoestrogens identified through the screening process described in 
chapters 3.2 and 3.3. 
A further aim was to determine whether treatment with any of these 
compounds could produce a response which would indicate that it had 
the potential to be an initiating factor in the development of PBC. 
 
3.4.1. Expression of estrogen receptors in vivo  
The expression of ERα and ERβ in the mouse were studied by RT-PCR. Tissue 
samples from both male and female C57Bl/6 mice were analysed using primers 
specific for either estrogen receptor isoform using standard RT-PCR protocols. 
Fig 3.24A shows that ERα was detectable in female liver, lung, brain and 
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uterus, and also in male liver, lung, brain and testis.  Expression of ERβ was 
confirmed in lung brain and uterus/testis of the animals, but was not detectable 
in the liver by this method. 
3.4.2. Acute exposure to estrogen causes portal tract inflammation in 
the mouse 
As part of a series of pilot studies, the effect of acute exposure to estrogen on 
portal tract inflammation (PTI) in the mouse was initially examined. Male 
C57Bl/6 mice were administered either E2, EE or vehicle control by i.p. injection 
on three consecutive days, following which the degree of portal tract 
inflammation was assessed and compared to that of a mouse subjected to 
ligation of the common bile duct (cBDL, a standard model of cholestatic liver 
disease).  Fig 3.24B shows that after treatment with E2 there was a significant 
increase in PTI over the vehicle control group, similar to that observed following 
cBDL. Treatment with EE did not result in any significant change in this study. 
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Figure 3.24 – A. Confirmation of the expression of the ER in the mouse by RT-PCR. 
Organs were harvested from adult male and female C56Bl/6 mice before isolation of RNA and 
subsequent RT-PCR using primers specific for the mouse ER. PCR products were visualised 
by agarose gel electrophoresis and UV transillumination B. Quantification of PTI in the 
mouse liver following treatment with estrogen. Adult male C57Bl/6 mice were treated with 
0.5mg/kg EE/E2 or vehicle control by single daily i.p. injection on 3 consecutive days before 
termination by schedule I method. Mean number of inflammatory cells per portal tracts were 
calculated. Animals subjected to cBDL or sham were used as a positive control for cholestatic 
liver injury. Data are mean and SD of 3 portal tracts per animal, n=4. *= Significant increase in 
PTI over relevant control (p<0.05) (Students t-test, two tailed). 
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The expression of the estrogen receptor in the mouse following treatment with 
E2 was examined by IHC, fig 3.25 shows that ERα is detectable at low levels in 
the hepatocytes in the normal mouse liver, and following treatment with E2. 
Positive ERα staining was observed to increase following common bile duct 
ligation (cBDL), a model for cholestatic liver disease. Whilst ERβ was not 
detectable in the liver by RT-PCR, positive staining for ERβ in the 
cholangiocytes and hepatocyte nuclei was observed in both control and E2 
treated animals in a model of acute estrogen exposure, following cBDL the 
expression of ERβ was observed not only in the cholangiocytes but throughout 
the hepatocytes, Fig 3.26. It is possible that ERβ is not detectable by RT-PCR 
as the expression is very low in the normal or mildly cholestatic mouse liver. 
This supports work previously documented by Alvaro et al who report that ERβ 
was not detectable in the normal human liver but in cholestatic liver conditions 
such as PBC, ERβ expression is up regulated92. 
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Figure 3.25 –Expression of ERα in the mouse liver by IHC. 5µm sections of formalin fixed 
and paraffin embedded mouse liver were stained with a primary antibody specific for ERα and 
HRP-conjugated secondary antibody, as described in chapter 2 – materials and methods. 
Sections were counterstained with haematoxylin. No primary antibody controls were included 
and stained as outlined, with the substituting ERα primary antibody with antibody diluent. 
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Figure 3.26 – Expression of ERβ in the mouse liver by IHC. 5µm sections of formalin fixed 
and paraffin embedded mouse liver were stained with a primary antibody specific for ERβ and 
HRP-conjugated secondary antibody, as described in chapter 2 – materials and methods. 
Sections were counterstained with haematoxylin. No primary antibody controls were included 
and stained as outlined, substituting ERβ primary antibody with antibody diluent. 
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3.4.2.1. Inflammatory infiltrate around the portal contract are of a 
mixed population which contain some NIMP positive cells 
The nature of the inflammation seen around the portal tracts in cholestasis is 
often poorly defined.  In an attempt to identify which cell types were present 
around the portal tracts following acute administration of estrogen, sections of 
mouse liver were stained by IHC for markers specific for different types of 
inflammatory cells. 
Fig 3.27 is a typical result of staining with an antibody specific for the NIMP 
antigen, the expression of which is specific to neutrophils. Fig 3.26B shows a 
cluster of NIMP positive cells in the liver, this is often observed and is possibly a 
localised immune response, it is used here as a positive control. Fig 3.27C 
shows a typical portal tract subject to a small amount of inflammatory infiltrate 
following treatment with E2, some of the inflammatory cells were positive for the 
NIMP antigen suggesting that neutrophils make up some of the inflammatory 
cells in E2 induced PTI. 
The antigen F4/80 is an extracellular membrane protein found on mature 
macrophages, Fig 3.28B shows the detection of Kupffer cells, the resident liver 
macrophage, by F4/80 specific antibody. No F4/80 positive cells were found in 
the portal tract inflammation of E2 treated mice, Fig 3.28C. 
CD3 refers to cluster of differentiation complex; it is a group of peptides that 
form part of the T-cell receptor complex found on mature T-lymphocytes.  Fig 
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3.29B shows the detection of CD3 positive cells in the mouse thymus. No CD3 
positive cells were found in the PTI of E2 treated animals, Fig 3.29C. 
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Figure 3.27 – Detection of cells expressing the NIMP antigen in PTI in the mouse liver. 
5µm sections of formalin fixed and paraffin embedded mouse liver were stained with a primary 
antibody specific for the NIMP antigen and HRP-conjugated secondary antibody, as described 
in chapter 2 – materials and methods. Sections were counterstained with haematoxylin, no 
primary antibody controls were included and stained as outlined, with the substituting NIMP 
primary antibody with antibody diluent. A; No primary antibody control. B positive control, C; 
portal tract of E2 treated animal 
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Figure 3.28 – No cells expressing the F4/80 antigen were detected in PTI in the mouse 
liver. 5µm sections of formalin fixed and paraffin embedded mouse liver were stained with a 
primary antibody specific for the F4/80 antigen and HRP-conjugated secondary antibody, as 
described in chapter 2 – materials and methods. Sections were counterstained with 
haematoxylin. No primary antibody controls were included and stained as outlined, with the 
substitution F4/80 primary antibody with antibody diluent. A; No primary antibody control. B 
positive control, C; portal tract of E2 treated animal 
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Figure 3.29 – No cells expressing the CD3 antigen were detected in PTI in the mouse 
liver. 5µm sections of formalin fixed and paraffin embedded mouse liver were stained with a 
primary antibody specific for the CD3 antigen and HRP-conjugated secondary antibody, as 
described in chapter 2 – materials and methods. Sections were counterstained with 
haematoxylin. No primary antibody controls were included and stained as outlined, with the 
substituting CD3 primary antibody with antibody diluent. A; No primary antibody control. B 
positive control, C; portal tract of E2 treated animal 
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3.4.3. Tartrazine and sunset yellow do not test positive for estrogenic 
activity by mouse uterine bioassay 
In the in vitro screening systems previously described, a number of compounds 
were found to have transcriptional estrogenic activity in human cell line models. 
The estrogenic effects of these compounds were examined in vivo. 
The mouse uterine bioassay is a classical method by which estrogenic activity 
can be assessed in vivo. In this system, pre-pubescent mice (19 d.o.) are 
administered potentially estrogenic compounds for 4 consecutive days by i.p 
injection. The effect of estrogen or other estrogenic compounds is an increase 
in uterine weight over the relative vehicle control group.   
Fig 3.30A describes the effect of treatment with sunset yellow, tartrazine, butyl 
paraben and methoxychlor on uterine development, relative to vehicle and E2 
controls.  Treatment of pre-pubescent mice with methoxychlor, a known 
xenoestrogen, resulted in a significant increase in wet uterine mass relative to 
total body mass. Administration of butyl paraben, which has previously been 
described to have estrogenic activity in this model, produced an increase in 
uterine weight which was approaching significance.  Treatment with sunset 
yellow or tartrazine did not produce any significant change in uterine weight. 
Examples of uteri from this study are shown in fig 3.30B, this clearly 
demonstrates the effect of E2 on uterine size. 
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Figure 3.30 –Uterotropic effects of xenoestrogen exposure in the mouse. A. 19 day old 
female C57Bl/6 mice were administered the described compounds by single i.p injection on 4 
consecutive days before excision of the uterus and calculation of the wet uterine weight 
relative to total body mass. Data are mean and SD of a minimum of n=4. *= Significant 
increase in relative uterine weight over vehicle control (p<0.05) (Students t-test, two tailed). B. 
Image of typical findings from mouse uterine bioassay. 
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3.4.4. In vivo model of xenoestrogen exposure on liver function in the 
mouse 
The effect of administration of the human ER activators, sunset yellow and 
tartrazine, alongside E2, on liver function were investigated in vivo.  Adult male 
C57Bl/6 mice were administered either E2, sunset yellow, tartrazine or relevant 
vehicle control (PBS or olive oil (OO)) 10 times in 14 days by i.p injection. 
Treatment concentrations were chosen based on the standard dose of E2 for 
inducing physiological estrogenic effects and the relative EC50 values calculated 
for the xenobiotics in vitro in the ERE-luciferase reporter gene assay described 
in chapters 3.1 and 3.2. Whilst PBC predominantly affects females, male mice 
were chosen for this model as the mouse menstrual cycle is short relative to the 
time of the study. It was reasoned that males would have a lower, and more 
consistent, level of circulating estrogen, and therefore would be a more 
accurate system. 
After treatment, animals were sacrificed and tested for a variety of different 
indicators which would link treatment with these any of these compounds to a 
risk of developing cholestatic liver disease or PBC. 
3.4.4.1. Administration of E2 and tartrazine both cause elevated 
serum ALP activity in the mouse 
Elevated serum alkaline phosphotase (ALP) levels are used as a clinical 
indicator of cholestatic liver disease.  Serum taken from mice treated with 
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sunset yellow, tartrazine or E2 was tested for serum ALP levels.  Fig 3.31 
shows that treatment with both E2 and tartrazine resulted in an increase in 
serum ALP over the relevant vehicle control. Whilst it is already understood that 
elevated estrogen levels can cause cholestasis, this data suggests that 
tartrazine may produce a similar cholestatic effect. 
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Figure 3.31 – Treatment with E2 and tartrazine cause elevated serum ALP activity in the 
mouse. Serum ALP activity following treatment 10 times in 14 days I.P. with 1mg/kg E2 (n=4), 
500mg/kg tartrazine (n=4), PBS (tartrazine vehicle, n=3) or 1:20 EtOH:OO (E2 vehicle, n=4). 
*=Significantly different (P<0.05) versus relevant vehicle control group, Student’s T-test (two 
tailed) 
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3.4.4.2. E2 and Tartrazine both cause increased PTI in the mouse 
The degree of PTI in this model was assessed using the same technique as in 
the model of acute estrogen exposure that was described at the beginning of 
this chapter. Fig 3.32 shows images of typical portal tracts following treatment 
with E2, sunset yellow, tartrazine or vehicle controls. It is clear that there is an 
increase in PTI following treatment with both E2 and tartrazine (highlighted by 
black arrow). This PTI was quantified, shown by fig 3.34A, both E2 and 
tartrazine resulted in a significant increase in PTI over the corresponding 
vehicle control group.  
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Figure 3.32 – Typical PTI in the mouse liver following treatment with E2 and tartrazine 
5µm sections of formalin fixed and paraffin embedded mouse liver were stained with 
haematoxylin and eosin as outlined in chapter 2, following treatment 10 times in 14 days by 
single i.p. injection with  A. PBS vehicle (sunset yellow/tartrazine vehicle). B. 1:20 EtOH:olive 
oil vehicle (E2 vehicle), C. 1mg/kg E2. D.  500mg/kg sunset yellow. E. 500mg/kg tartrazine.  
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3.4.4.3. Treatment with E2 and tartrazine both cause increased 
collagen deposition around the portal tracts of the mouse 
liver. 
Collagen deposition is synonymous with fibrosis, typically in cholestatic liver 
disease and in PBC, an increase in collagen deposition is observed around the 
portal tracts. The degree of collagen deposition following treatment with 
xenoestrogens was examined by quantitative analysis of Sirius red staining 
around the portal tracts. Fig 3.33 shows images of typical portal tract areas 
following treatment and reveals that there is an increase in collagen deposition 
(highlighted by black arrow) following treatment with both E2 and tartrazine 
relative to vehicle controls. The degree of positive Sirius red staining was 
quantified and is shown in Fig 3.34B, treatment of mice with both E2 and 
tartrazine caused a significant increase in positive staining.  
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Figure 3.33 – Typical Sirius red staining in the mouse liver following treatment with E2 
and tartrazine 5µm sections of formalin fixed and paraffin embedded mouse liver were 
stained with Sirius red for collagen as outlined in chapter 2, following treatment 10 times in 14 
days by single i.p. injection with  A. PBS vehicle. B. 1:20 EtOH:Olive oil vehicle, C. 1mg/kg 
E2. D.  500mg/kg sunset yellow. E. 500mg/kg tartrazine.  
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Figure 3.34 Analysis of portal tract injury following treatment with xenoestrogens A –
Treatment with E2 and tartrazine causes a significant increase in PTI in the mouse liver 
5µm sections of formalin fixed and paraffin embedded mouse liver were stained with 
haematoxylin and eosin as outlined in chapter 2, following treatment 10 times in 14 days by 
single i.p. injection with either 1mg/kg E2 (n=4), 500mg/kg sunset yellow (n=4) 500mg/kg 
tartrazine (n=4), PBS (sunset yellow/tartrazine vehicle, n=3) or 1:20 EtOH:OO (E2 vehicle, 
n=4). Mean number of inflammatory cells were counted for 8 portal tracts per animal. B. 
Treatment with E2 and tartrazine causes a significant increase in collagen deposition in 
the mouse liver. 5µm sections of formalin fixed and paraffin embedded mouse liver were 
stained with Sirius red as outlined in chapter 2, following treatment 10 times in 14 days by 
single i.p. injection with either 1mg/kg E2 (n=4), 500mg/kg sunset yellow (n=4) 500mg/kg 
tartrazine (n=4), PBS (sunset yellow/tartrazine vehicle, n=3) or 1:20 EtOH:OO (E2 vehicle, 
n=4). Mean amount of positive staining was quantified for 8 different fields of view per animal. 
*= Significant increase control group (p<0.05) (Students t-test, two tailed). 
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3.4.4.4. Estrogen and xenoestrogen exposure causes altered 
bile/drug transport protein expression in the mouse liver 
The relative expression of a range of transporter proteins which are involved in 
uptake/ efflux of bile acids were analysed by SYBR green qRT-PCR following 
treatment with estrogen or the ER activating compounds sunset yellow and 
tartrazine. 
Elevated exposure to estrogen has previously been described to cause 
changes in expression of certain transporter proteins in the rat and the 
mouse108, 109, this provides a potential mechanism for the cholestasis 
sometimes seen in response to elevated serum estrogen levels. The expression 
genes encoding known or potential bile acid transporters was assessed in this 
mouse model of xenoestrogen exposure. 
The Abcc family of genes encode a number of membrane transport proteins in 
the super family of ATP binding cassette (ABC) transporters. Abcc1-6 encode 
multidrug resistance associated proteins 1-6 (MRP1-6) respectively, all of which 
are expressed in the normal liver at varying levels110. The expression of Abcc1-
6 in the mouse liver was examined by quantitative PCR following treatment with 
E2, sunset yellow and tartrazine. 
Fig 3.35 shows that expression of Abcc1 was unchanged following treatment, in 
contrast, administration of E2 caused a significant decrease in expression of 
Abcc2 relative to vehicle control, sunset yellow and tartrazine had no significant 
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effect on level of Abcc2. MRP3 is reported to be the most highly expressed of 
this family of proteins in the liver, the expression of Abcc3, which codes for this 
protein was significantly down regulated by both E2 and tartrazine in the 
mouse. Bile salts are known to be good substrates for MRP3111  No significant 
changes in Abcc4 levels were observed, though this gene was found to be 
variable in its expression in the mouse, supporting evidence for its variable 
expression profile describe in the human reported previously 112. Abcc5 has 
been reported to be expressed at moderate levels in the mouse liver relative to 
other members in this family, Abcc5 gene was significantly up regulated by 
tartrazine in this model. A trend towards a decrease in Abcc6 expression was 
observed following treatment with both E2 and tartrazine, although this was not 
statistically significant probably due to variability of Abcc6 expression. 
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Figure 3.35 –Expression of Abcc family of transport proteins in the mouse liver 
following treatment with xenoestrogens. Expression of Abcc1-6 in the mouse liver was 
quantified by SYBR Green qRT-PCR following treatment 10 times in 14 days by single i.p. 
injection with either 1mg/kg E2 (n=4), 500mg/kg sunset yellow (n=4) 500mg/kg tartrazine 
(n=4), PBS (sunset yellow/tartrazine vehicle, n=3) or 1:20 EtOH:OO (E2 vehicle, n=4) *= 
significantly different to vehicle control group (p<0.05) (Students t-test, two tailed). 
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It has previously been reported that expression of the gene Abcb11, which 
encodes the bile salt export pump (BSEP) is down regulated following estrogen 
exposure in the rat109. In this study, a trend towards a decrease in BSEP 
expression was observed, but this effect was not statistically significant due to 
outlying results. 
The gene Slc10a1 encodes the sodium (Na+) taurocholate co-transporting 
polypeptide (NTCP), a bile salt transport protein expressed on the hepatic 
sinusoid113. Expression of this gene was significantly down regulated in the 
mouse following treatment with sunset yellow. 
Permeability glycoprotein (p-gp), encoded by Abcb1b, is a well-characterised 
transporter belonging to the ABC super family. It is expressed on the canalicular 
membrane of hepatocytes and is associated with xenobiotic clearance and drug 
resistance114. Treatment with tartrazine was found to significantly increase 
Abcb1b expression in the mouse liver. 
The inflammatory cytokine Interleukin-1-β (Il1β) has previously been shown to 
be induced in the mouse liver following treatment with estrogen.  The 
expression of Il1β was examined in the model of xenoestrogen exposure, it was 
found that ILβ1 was elevated by treatment with E2, but whilst this result was 
approaching statistical significance, once again variability between the animals 
was evident. 
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The expression of both ERα and ERβ were also studied by SYBR green qRT-
PCR. The expression of ERα in this model was not altered following treatment 
with E2, sunset yellow or tartrazine.   
As described previously, ERβ expression was not detectable by standard RT-
PCR methods and agarose gel electrophoresis in the mouse liver. But by qPCR 
methods a single product was detected, possibly due to the sensitivity of this 
system.  Treatment of mice with sunset yellow caused a large decrease in 
expression of ERβ at the mRNA level, no effects relating to the expression of 
ERβ following treatment with E2 or tartrazine were seen. This may imply that 
the level of cholestasis necessary to cause a significant increase in ERβ mRNA 
was not reached in this model. (Fig 3.36) 
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Figure 3.36 –SYBR green qRT-PCR analysis of gene expression in the mouse liver 
following treatment with xenoestrogens. Expression of selected genes in the mouse liver 
was quantified by SYBR Green qRT-PCR following treatment 10 times in 14 days by single 
i.p. injection with either 1mg/kg E2 (n=4), 500mg/kg sunset yellow (n=4) 500mg/kg tartrazine 
(n=4), PBS (sunset yellow/tartrazine vehicle, n=3) or 1:20 EtOH:OO (E2 vehicle, n=4) *= 
significantly different to vehicle control group. (p<0.05) (Students t-test, two tailed). 
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3.4.4.5. Exposure to estrogen causes increased serum AMA titre in 
the mouse 
The presence of antimitochondrial antibodies (AMA) in PBC patient sera is 
observed in around 95% of cases, and is normally considered the defining 
hallmark of PBC. Indeed serum AMA titre is used clinically as a marker of 
PBC101. 
An established ELISA system of measuring AMA titre in the mouse was used to 
measure serum AMA levels in the mouse model of xenoestrogen exposure95. 
Fig 3.37A shows that treatment of mice with E2 resulted in a significant increase 
in serum AMA titre over vehicle control group. Treatment with tartrazine did 
increase AMA titre over the PBS control group, but variability between animals 
resulted in a loss of statistical significance. 
Differences in the level of in the response of animals in this study to tartrazine 
was something that was noticed in both the PTI and Sirius red quantification 
performed previously. It was for this reason that the AMA titre was compared to 
the level of PTI for each animal. Fig 3.38 describes the result of plotting AMA 
titre against the PTI score for each animal, it is evident that there is a correlation 
between the level of AMA titre and PTI, suggesting that the AMA levels in 
response to treatment with E2 or tartrazine are dependent on the degree of liver 
insult.  Vehicle control groups and sunset yellow, which had no effect on any 
other markers of damage or cholestasis, lay in the lower values of both 
measurements. 
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Figure 3.37 –Serum AMA activity in the mouse following treatment with xenoestrogens. 
A. Mouse serum AMA activity against murine PDC-E2 was analysed by ELISA following 
treatment 10 times in 14 days by single i.p. injection with either 1mg/kg E2 (n=4), 500mg/kg 
sunset yellow (n=4) 500mg/kg tartrazine (n=4), PBS (sunset yellow/tartrazine vehicle, n=3) or 
1:20 EtOH:OO (E2 vehicle, n=4) *= significantly different to vehicle control group. (p<0.05) 
(Students t-test, two tailed). B. Serum AMA activity against murine PDC-E2 of positive control 
sera from mice immunised with foreign PDC-E2. 
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Figure 3.38 – Correlation between serum AMA activity and severity of cholestatic liver 
injury. Plot of serum AMA activity against PTI count in a mouse model of xenoestrogen 
exposure. Mice were treated 10 times in 14 days by single i.p. injection with 1mg/kg E2 (open 
circle)(n=4), 500mg/kg tartrazine (open square) (n=4), 500mg/kg sunset yellow (filled 
square)(n=4), PBS (filled diamond)(tartrazine/sunset yellow vehicle, n=3), or 1:20 EtOH:OO 
(filled circle)(E2 vehicle, n=4). 
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3.4.5. Chapter 3.4 discussion 
In this chapter the effects of exposure to estrogen as human ER activators 
in chapter 3.2 were studied in vivo.   
The expression of both ERα and ERβ was determined in the mouse by RT-
PCR and immunohistochemistry. Expression of ERα was found to be 
widespread throughout the hepatocytes, whilst ERβ was undetectable by 
RT-PCR, but was observed at the protein level in cholangiocytes 
(accounting for only around 5% of liver cells) by IHC.  
An acute study of estrogen exposure in male mice showed that 3 days of 
treatment with E2 resulted in a significant increase in portal tract 
inflammation. The nature of this PTI was examined and was found to be of 
a mixed cell type, consisting of at least some NIMP positive cells, 
suggesting the presence of neutrophils. 
Utilising the classical mouse uterine bioassay, the human ER activators 
sunset yellow and tartrazine were found to have no uterotrophic effects.  
In a 2 week study of estrogen/xenoestrogen exposure in the mice, both 
E2, as before, and the food and cosmetic colouring agent, tartrazine, were 
found to significantly increase PTI in the mouse. Both of these 
compounds also caused a significant increase in positive Sirius red 
staining in the liver and also an elevation in serum ALP levels, 
synonymous with cholestasis. 
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The expression of bile salt transport proteins and efflux pumps was 
examined by SYBR green qRT-PCR.  The expression of some of these 
genes was found to be altered following treatment with E2, sunset yellow 
or tartrazine, in concordance with previous work which suggest that 
estrogen induced cholestasis is in some part linked with altered 
expression profile of membrane transport proteins. It is worth mentioning 
that a lot of variability between animals was observed in this study, which 
had relatively small group numbers. This may have masked positive 
results or statistical significance. 
The expression of CYP 3a11, a well described PXR dependent gene in the 
mouse was comprehensively down regulated by both E2 and tartrazine. 
PXR activation has previously been shown to be protective against liver 
injury, and also has been reported to drive the expression of the MRP 
family of ABC transporters115. This may be caused by PXR antagonism by 
both E2 and tartrazine, resulting in altered transporter expression, 
cholestasis and also a reduced capacity for liver recovery. 
The expression of ERα was found to be unaffected following treatment 
with any of the selected compounds, but sunset yellow comprehensively 
down regulated ERβ mRNA levels. 
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The presence of AMA in mouse sera was studied following exposure to 
the same set of compounds. E2 exposure was found to increase serum 
AMA activity over controls, tartrazine did appear to increase titre but fell 
short of statistical significance due to variability, but a correlation was 
discovered between the degree of PTI and serum AMA titre, suggesting 
that appearance of AMA may be proportional to the severity of estrogen 
induced cholestatic liver injury. 
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3.5. Isolation, characterisation and proliferation of cells 
isolated from the intrahepatic biliary structure. 
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The intrahepatic biliary structure describes the network of bile duct which 
form a ‘tree’ like structure running throughout the liver. This network of 
bile ducts and smaller ductules is comprised primarily of cholangiocytes, 
but is also thought to be the location of resident hepatocyte and 
cholangiocyte progenitor cells116, 117. It is possible to separate the entire 
biliary tree from the rat liver by collagenase digestion.  From this structure 
cultures of cells were prepared and characterised to determine which cell 
types were present.  The effect of estrogen upon the proliferation and 
differentiation of these cell cultures was examined. 
3.5.1. Isolation of cell cultures from the intrahepatic biliary structure. 
After collagenase perfusion and digestion of the rat liver, the whole biliary 
structure was retained, digested and filtered before culturing the resulting cells. 
Whilst the initial aim of producing primary cell cultures of cholangiocytes to 
simulate the population of the bile duct in vitro was apparently unsuccessful, it 
was evident that the actual product of these preparations may be much more 
significant.   
Limited amounts of small (>10x smaller than an average primary hepatocyte), 
round cells, either individual or in clusters of no more than 5, were produced. 
Upon seeding these cells in standard tissue culture dishes and 2 days of 
culture, they formed tight clusters of cells as a 3 dimensional mass as shown in 
Fig 3.39A.  After 5 days of culture, these original clusters of cells remained, but 
radiating from them were two distinctly different cell types, evident in figs 3.39 
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B,C,D.  It was also discovered that these cultures would often form circular 
structures at the boundary of the original cell masses such as the one shown in 
Fig 3.39E. After passage, the original structures of cells were no longer present 
and only one cell type was observed in the cultures. Fig. 3.39F.  
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Figure 3.39 –Mixed cell cultures of cells isolated from the rat biliary structure. Bright 
field imaging of mixed cell cultures isolated from the intrahepatic biliary structure of the rat 
liver, A. t=48 hours, B. t=5 days. C. t=5days, D. t=5days. E. t=5 days. F. Passage 1. 
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3.5.2. Cell cultures isolated from the intrahepatic biliary structure 
contained an OV-6 positive progenitor, giving rise to 
cholangiocytes and fibroblasts 
The cell types within the cultures were characterised by immunocytochemistry, 
fixed cell cultures were stained for a variety of different antigens, including OV-
6, cytokeratin 19 (CK19), vimentin and albumin, the results are shown in Fig 
3.40.  Cells positive for the OV-6 antigen, deemed to be a marker of the 
resident liver progenitor cell, the oval cell, were observed only at the centre of 
the initial cell clusters118. Of the proliferating cells, one cell type was positive for 
CK19, whilst the other cell type was positive for vimentin. This suggests that the 
cells produced were a mixture of CK19 positive cholangiocytes and vimentin 
positive fibroblasts.  Vimentin was also detected in the original cell clusters, this 
is concordant with previous findings that cultured stem cells often form a 
fibroblastic niche around themselves in vitro.  In these areas both CK19 and 
albumin (a marker of hepatocytes, which has also been detected in both 
immature hepatocytes and precursor cells of the intrahepatic bile duct.)119  
The expression of CK19 and vimentin was profiled throughout time in culture by 
RT-PCR using primers specific to each gene.  Fig 3.41 shows that CK19 was 
detected in freshly isolated cells, and up to 3 days of culture after which CK19 
mRNA was undetectable.  The expression of vimentin mRNA was detectable at 
all of the time points examined, including after passage. This confirms that 
CK19 positive cholangiocytes were present in culture for up to 3 days after 
isolation, whereas fibroblasts were present throughout culture. This suggests 
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that either the cholangiocytes present in the earlier stages of culture either 
differentiate/ de-differentiate to fibroblasts over time, or undergo cell death 
leaving the fibroblasts to take over the culture. Albumin was detectable only at 
t=0. 
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Figure 3.40 –ICC study of mixed cell cultures isolated from the rat intrahepatic 
biliary structure. Rat biliary cell preparations were formalin fixed in situ after 3 days of 
culture. Cells were incubated with the indicated primary antibody and corresponding 
fluorescent secondary. And counter staining with DAPI before imaging by fluorescence 
microscopy. Relevant no-primary controls included where primary antibody was 
substituted for antibody diluent.antibody diluent 
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Figure 3.41 – Profile of CK-19, albumin and vimentin expression in biliary cell 
preparations throughout culture. Biliary cells were cultured for the indicated number of 
days before RNA isolation and RT-PCR with primers specific for CK19, albumin or 
vimentin as described in chapter 2 – materials and methods. Visualisation was performed 
by agarose gel electrophoresis and UV transillumination.  
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3.5.3. Cell cultures isolated from the intrahepatic biliary stucture of the 
rat express common pluripotency/progenitor factors 
Based upon the identification of both OV-6 and albumin antigens within the 
cultures prepared from the intrahepatic biliary structure by 
immunocytochemistry, the expression of various genes synonymous with 
progenitor cells and pluripotency were profiled throughout time in culture, by 
RT-PCR. 
The expression of sox17, a gene linked with endodermal development and cell 
fate that may commonly be expressed in progenitor cells of epithelium of the 
respiratory and gastrointestinal tracts, along with the liver, lung and pancreas 
was detectable in biliary cell cultures at 0 and 3 days in culture, after which 
expression was not detectable120. 
The pluripotency factor Sox2, the expression of which is regarded as essential 
for maintenance of undifferentiated stem cells, was detectable at t=0, but not at 
any other point. Expression of two other pluripotency factors considered good 
indicators of stem cell like capacity, Klf4 and c-Myc121, 122 , were detected at all 
stages of culture of the primary biliary cell preps, however, expression was lost 
after passage. Expression of Oct4, a fourth transcription factor regarded as 
essential in induction and regulation of pluripotency, was not detected in the 
cultures121, 122 (Fig 3.42). 
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Figure 3.42 – Profile of the expression of pluripotency factors and the ER in biliary 
cell preparations . Biliary cells were cultured for the indicated number of days before 
RNA isolation and RT-PCR with primers specific for the described genes as described in 
chapter 2 – materials and methods. Visualisation was performed by agarose gel 
electrophoresis and UV transillumination.  
  
Chapter 3 - Results 
203 
3.5.4. Estrogen causes increased proliferation of biliary cell cultures 
As previously described, PBC is characterised by proliferation of the 
intrahepatic bile ducts, accompanied by portal and periportal fibrosis.  The 
cultures of cells which were isolated from the intrahepatic biliary network of the 
rat liver and characterised in the previous section provide a good model in 
which to examine the effects of estrogen treatment upon the bile ducts. 
Cultures of biliary cells were treated with either 0.1% DMSO vehicle, 
10nM/10µM E2 or 10µM EE (all +/- 100nM ICI 182780). Cells were treated for 5 
days before analysis.  Fig 3.43A shows images of typical fields of view of both 
the DMSO vehicle and 10µM E2 groups. The numbers of cells of 5 such fields 
of view, selected at random, in three separate studies were counted, shown by 
fig 3.43B.  These results show that treatment with 10µM E2 significantly 
increased the number of cells present relative to the DMSO vehicle group. In all 
cases, treatment with 100nM ICI 182780 significantly reduced the number of 
cells present, compared to the relevant treatment group. 
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Figure 3.43 –. Effect of E2 on the proliferation of biliary cell cultures. A. Typical 
images of biliary cell preparations following treatment with 10µM E2 or DMSO vehicle, +/- 
100nM ICI 182780, for 5 days. Cell cultures were the formalin fixed in situ before imaging 
by bright field microscopy at 20x magnification. B. Quantification of mean number of cells 
per field of view from images of biliary cell preparations following treatment with 
10nM/10µM E2 or DMSO vehicle, +/- 100nM ICI 182780, for 5 days. Cell cultures were 
the formalin fixed in situ before imaging by bright field microscopy. Data are mean and SD 
of n=3. *= Significantly increase, over DMSO vehicle**=significant decrease over no 
antagonist group. (p<0.05) (Students t-test, two tailed) 
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The effects of treatment on cell proliferation were also analysed by 
quantification of total protein by actin western blot.   This method of analysis did 
not confirm an increase in total protein per well following treatment with E2, but 
did show that the estrogen receptor antagonist, ICI 182780, significantly 
decreased total protein, concordant with findings from the cell counts (Fig 3.44 
A,B). 
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Figure 3.44 –. Effect of E2 on the proliferation of biliary cell cultures. A. Western Blot 
for β-actin for a fixed volume of total protein taken from cell cultures isolated from the rat 
biliary structure following treatment with 10nM/10µM E2 or DMSO vehicle, +/- 100nM ICI 
182780, for 5 days. 20µl of protein sample/lane B. Quantification of actin Western blot for 
a fixed volume of total protein taken from cell cultures isolated from the rat biliary structure 
following treatment with 10nM/10µM E2 or DMSO vehicle, +/- 100nM ICI 182780, for 5 
days. Data are mean and SD of n=3. *= Significant decrease to control group. (p<0.05) 
(Students t-test, two tailed). 
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To study whether treatment of cell cultures with estrogen has an effect on their 
differentiation, or rate of proliferation between cholangiocytes and fibroblasts, 
vimentin expression was quantified relative to total actin. The results shown in 
Fig 3.45A,B suggest that there is no change in the amount of vimentin relative 
to total actin in response to treatment with either E2 or ICI 182780, and 
therefore it is unlikely that there is a shift towards either fibroblasts or 
cholangiocytes in culture. 
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Figure 3.45 –. Effect of E2 on the differentiation of biliary cell cultures. A. Western Blot 
for β-actin and vimentin for a fixed volume of total protein taken from cell cultures isolated 
from the rat biliary structure following treatment with 10nM/10µM E2 or DMSO vehicle, +/- 
100nM ICI 182780, for 5 days. 20µl of protein sample/lane B. Quantification of vimentin 
Western blot expressed relative to total actin for a fixed volume of total protein taken from cell 
cultures isolated from the rat biliary structure following treatment with 10nM/10µM E2 or 
DMSO vehicle, +/- 100nM ICI 182780, for 5 days. Data are mean and SD of n=3.  
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3.5.5. Chapter 3.5 discussion 
This chapter has described the isolation of cells from the intrahepatic 
biliary structure that proliferate to form a mixed population of cells, 
similar to that which may be found in the bile duct in vivo. These cell 
cultures were found to be positive for both OV-6 and albumin antigens, 
suggesting that the initial clusters of cells that were isolated have some 
stem cell like characteristics.  
Further analysis of gene expression in these cell cultures revealed that 
they express Sox 17, a marker of progenitor cells whose fate may be 
endodermal epithelium, liver or pancreatic cell types.  The cell cultures 
also expressed c-Myc and Klf4 up until the point of passage, and Sox 2 at 
the point of isolation. These transcription factors are thought to be 
essential in both native and induced pluripotency and there detection is 
further evidence of the presence of a form of liver progenitor cell within 
the cultures.  Based on the expression of OV-6 which is widely regarded 
as a specific marker for oval cells, they may be identified as such. 
However, Oval cells are poorly defined and it is equally possible that OV-6 
is a marker of a wider range of liver progenitor cells. 
These cell cultures were discovered to be sensitive to estrogen exposure, 
which had some regulatory action upon their rate of proliferation, this may 
suggest that the mechanism of bile duct proliferation in estrogen 
cholestasis or PBC is as a direct response to the estrogen itself.  
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Estrogen was not found to alter the balance of fibroblasts to epithelial 
cells in culture so it may be possible that some other factor, possibly the 
toxicity of an environmental xenoestrogen, is required to induce fibrosis 
of the bile ducts seen in PBC. 
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4. General discussion 
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The initial aim of this research project was to identify xenobiotic compounds that 
may have the potential to initiate PBC through interactions with the ER.  
Although it has not been discussed at length in this thesis, the first method 
employed to achieve this specific aim was to find a reliable estrogen responsive 
gene in rat hepatocytes, the expression of which could be measured by 
quantitative PCR. It became apparent that this would not be possible as the 
response to a variety of different genes, previously reported to be estrogen 
responsive in the liver was found to be variable and inconsistent. The decision 
was made at that point to find an alternative method for measurement of 
transcriptional activity. 
The subsequent development of an estrogen receptor-luciferase reporter 
construct was ultimately very beneficial. It allowed for thorough determination of 
the specificity of the resulting estrogen screening system and confirmation that 
transcriptional estrogenic activity mediated by both ERα and ERβ. This method 
was coupled with the well-defined induction of TFF1 by estrogen receptor 
activation in MCF-7 cells. Estrogen induced TFF1 expression in estrogen 
responsive breast cancer cells has been investigated at length by cancer 
research groups96 and was used to provide assurance the findings that 
emerged from the luciferase reporter work. 
Primarily using the (ERE)3-pGL3-promoter luciferase screening system, groups 
of xenobiotics were assessed for transcriptional estrogenic activity in the MCF-7 
breast carcinoma cell line. From these experiments, the transcriptional 
estrogenic activity of a number of compounds was discovered, and the activity 
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of other previously reported xenoestrogens was confirmed. These findings were 
corroborated by measurement of TFF1 expression.  It is worth noting that some 
compounds appeared to inhibit the estrogen receptor in these experiments. 
By performing dose-response investigations using the (ERE)3-pGL3-
promoter/MCF-7 system it became apparent that the potency of the identified 
xenoestrogens, sunset yellow, tartrazine, propyl paraben and butyl paraben 
was much lower (>50x lower) than E2.  This suggested that whilst these 
compounds do appear to activate the human ER, a very high level of exposure 
might be required to produce comparable effects to those of pure estrogens in 
vivo.   
Primary rat hepatocytes were used to study the effects of hepatic metabolism 
on the estrogenic activity of a smaller set of xenobiotics. These experiments 
proved difficult to perform as the estrogen response from different liver 
perfusions proved highly variable, and transfection of the necessary plasmids 
was inefficient. Despite these obstacles, the data obtained revealed that some 
xenobiotics, which were not estrogenic in MCF-7 cells, did appear to activate 
the rat ER in hepatocytes. This could be due to the requirement for metabolism 
to form reactive metabolites with estrogenic activity, or equally could indicate a 
species difference in substrate specificity between humans and rats.  This could 
be explored further by repeating the investigation in primary human 
hepatocytes, an experiment that was attempted but the cells were repeatedly 
untransfected. 
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By utilising non estrogen responsive cell lines and ectopic expression of the 
different estrogen receptor subtypes, ERα and ERβ, it was observed that 
tartrazine showed a greater affinity for ERβ whilst sunset yellow was ERβ 
specific in both MDA and H69 cells. 
Following the identification of sunset yellow and tartrazine as hER activators, 
the effects of these compounds on mitochondrial function was investigated. The 
hypothesis was proposed that whilst the potency of the estrogenic activity of 
these xenobiotics was low in comparison to E2, if these compounds also 
caused a degree of mitochondrial toxicity they might be candidate triggers for 
PBC.  It was discovered that sunset yellow caused a decrease in MTS reduction 
in primary rat hepatocytes, This was an indication that sunset yellow exposure 
may cause alterations to mitochondrial energetics, to which PDC enzymes are 
critical. Another clear difference between sunset yellow and tartrazine was 
observed, with the latter not producing the same hepatotoxic effects.  
The inhibition of MTS reduction by sunset yellow was intensified in the presence 
of DTT. It is known that a major route of metabolism of azo dyes is via bacterial 
reduction in the gut107. It is feasible that DTT may act as an electron donor to 
reduce sunset yellow further that is possible by cultures hepatocytes and that 
this reduced metabolite is more damaging to mitochondrial function. It is 
important to point out that it has been suggested previously that other enzymes 
including those involved in hepatic metabolism can also reduce MTS. It is not 
possible to conclude from this assay the precise effects of sunset yellow on 
mitochondrial viability. Another point of consideration is that MTS assay is a 
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colorimetric method, and despite careful experimental planning and 
normalisation to controls, there may be some degree of noise or interference.  
A second measure of mitochondrial function was implemented. By measuring 
the localisation of TMRM following treatment, the mitochondrial membrane 
potential was examined. These data showed that treatment with relatively low 
concentrations of sunset yellow and tartrazine caused an accelerated loss of 
mitochondrial polarisation, supporting the evidence for these compounds to 
have a negative effect on mitochondrial function. Whilst these studies of may 
imply that exposure to certain xenoestrogens causes a loss of mitochondrial 
function, it must be accepted that the effects seen in these assays may be due 
to cell death or proliferation effects resulting in a decreased number of 
mitochondria. Without performing cell proliferation/total protein it is impossible to 
clarify the underlying cause. 
In a pilot study of estrogen exposure in the mouse, acute exposure to E2 was 
found to significantly increase PTI, this supports the previous work surrounding 
the cholestatic effect of estrogens. However this same earlier work has found 
similar effects following administration of EE, but in our model EE did not 
produce the same elevation in PTI as E2. 
A range of xenobiotics, including sunset yellow and tartrazine, were tested for 
estrogenic activity using the classical mouse uterine bioassay. In this model 
only long-established xenoestrogens, such as methoxychlor, caused a 
significant acceleration in uterine development123. Taking into account that ERβ 
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is not deemed critical in sexual development it is reasonable to suggest that the 
uterotrophic assay is a screen for ERα activity124. Having previously indicated 
that both sunset yellow and tartrazine appear to show higher affinity for the β 
receptor subtype in vitro, this offers an explanation to why they tested negative 
in the mouse assay. 
In a separate in vivo model it was observed that tartrazine caused a similar 
cholestatic liver injury to E2, both treatments resulted in increased serum ALP 
activity, PTI and positive sirius red staining in the mouse.  Despite not having an 
effect on uterine development, tartrazine produces a similar liver injury to E2. As 
the primary estrogen receptor in human cholangiocytes has been shown to be 
the β form, the expression of which is up regulated in cholestasis and in PBC, 
this is further evidence for the importance of ERβ activation in cholestatic liver 
injury arising from estrogen/xenoestrogen exposure92.  
Sunset yellow did not produce the same effect as tartrazine and E2, a potential 
explanation for this is that azo dyes are metabolised in part by reduction 
facilitated by gut bacteria, by administering these compounds by i.p. injection 
bypasses this system, which may be required for the bioactivation of some azo 
compounds. It would be worthwhile to repeat the same investigation and 
administer the treatment by oral gavage to investigate this further. The 
expression of a variety of membrane transport proteins were also analysed in 
this study. These data show that E2, tartrazine and sunset yellow all have 
effects on expression of the family of genes which encode MRP transporters 
and also other hepatic transport proteins. The expression of bile salt 
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transporters has been investigated previously in the context of estrogen 
cholestasis. Despite noticing alterations in expression of these genes, the 
results of our study did not always concur with previous work, high degree of 
variability between animals, and small group numbers may in some way 
accounted for this effect. 
The expression of CYP3a11 in the mouse was analysed following treatment 
with xenoestrogens. It was found that both E2 and tartrazine caused a 
significant down regulation of this PXR dependant gene, implying a level of 
PXR antagonism. It has been previously documented that the PXR controls the 
expression of certain hepatic transport proteins, significantly MRP3115. The 
inhibition of Abcc3 gene (coding for MRP3) by E2 and tartrazine supports a 
theory of estrogenic PXR antagonism as a potential mechanism for the altered 
transport protein expression profile seen in estrogen cholestasis. As PXR 
activation has been reported to be beneficial in liver regeneration, its inhibition 
could cause a ‘double hit’ by also reducing the capacity for liver recovery. 
The presence of AMA, or elevated serum antibody activity against PDC 
enzymes, is considered the hallmark of PBC. Following exposure to tartrazine, 
no significant increase in sera AMA activity over vehicle control was observed in 
the mouse. E2 did cause a significant increase in AMA activity, but again there 
was a lot of inter animal variability and small group numbers that reduced the 
statistical power of the study.  A correlation was made between the serum AMA 
titre and the severity of liver injury in that animal. Remembering that AMA are 
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not detectable in all PBC patients, possibly AMA are not a causative factor in 
PBC, but merely an indication of the disease state.  
Through the isolation of mixed cell populations from the intrahepatic biliary 
structure of the rat liver, it was possible to study the effect of estrogen exposure 
on growth and differentiation.  It was observed that E2 caused an acceleration 
in the rate of proliferation of these cells, their differentiation was unchanged. It 
was not possible to examine the effects of the xenoestrogens tartrazine and 
sunset yellow, as the work with primary rat liver cells became impossible due to 
an unknown problem resulting in a decline in cell viability. 
The in vivo studies of xenoestrogen exposure used exceptionally high doses of 
sunset yellow and tartrazine. Which were calculated based upon the EC50 
values from the in vitro screening systems. It is unrealistic that a person would 
ever be exposed to such a high concentration of a food dye. The maximum 
exposure to tartrazine, reported by the European food safety authority, is in the 
region of 8mg/kg body weight per day. There is potential for significant 
geographical variation in the exposure to azo compounds to occur. Those 
populations located close to industrial areas concerned with the dye industry, 
for example, may be exposed to significantly higher levels of azo dyes that 
other populations. And whilst it is already understood that there is an increased 
incidence of PBC in certain industrial areas, it would be interesting to map the 
incidence of PBC with the manufacture/use of these compounds.  
Chapter 4 – General discussion 
219 
During the cause of the preparation of this thesis, the possible role of xenobiotic 
exposure in the initiation or progression of PBC has become more widely 
acknowledge.  Research into geographical variance of the incidence of PBC 
has previously highlighted the north east of England as a ‘hotspot’ for PBC125. 
Recent epidemiological studies amongst populations of PBC patients, such as 
those in the north east of England, have revealed a number of environmental 
risk factors , including the use of hair dyes and smoking. These same studies 
also show potential links between those who have previously been diagnosed 
with obstetric cholestasis126.  
More recently, research to understand the mechanisms by which chemical 
compounds may be act to cause the development of PBC and more specifically 
the loss of tolerance to self PDC-E2 has suggested that some xenobiotics may 
disrupt the domain of PDC-E2 may disrupt the S-S disulphide. This may render 
it in a reduced state that could be susceptible to modification by any of a 
number of common electrophiles such as acetaminophen and other non-
steroidal anti-inflammatory drugs (NSAIDs)127. 
This thesis has described how certain xenobiotics, routinely found in products, 
to which the frequent use of has been linked to increased incidence of PBC, 
can activate the human ER and cause a cholestatic liver injury in the mouse. 
This may cause and increase in ERβ expression alongside PXR antagonism, 
both of which may form a positive feedback mechanism causing and intensified 
and perpetuating cholestatic condition. 
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Whilst no definitive answers have been proposed, the evidence presented 
suggests that exposure to certain environmental xenoestrogens may be one of 
multitude of factors, including genetic susceptibility and predisposition to 
estrogen cholestasis or cholestatic liver disease, implicated in the development 
and progression of PBC. 
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6.      Communication and Awards 
 
COMMUNICATION  
• NEPG Conference 2011 
• ISHSR 2011 
• BTS Autumn Conference 2011 
• ISHSR 2010 
• BTS annual congress 2009 
AWARDS 
• The British Toxicology Society Best Presentation Award 2011 
• BTS Travel Award Bursary 2011 
• ISHSR Travel Award Bursary 2010 
• BTS travel award bursary 2009 
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